Small molecule inhibitors of NF-[kappa] B-inducing kinases
By developing small molecule inhibitors to block the activation pathway of NIK, the immune response disorders and inflammation caused by NIK overactivity are addressed, and potential treatment options for related diseases are provided.
Patent Information
- Application Number
- CN202410972792.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-30
- Filing Date
- 2020-05-29
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively inhibit the overactivity of NF-κB-induced kinase (NIK), leading to the occurrence of diseases such as immune response disorders, inflammation and cancer.
A class of small molecule inhibitors has been developed to compete to bind to the activation pathway of NIK through specific structures, blocking their activation, thereby inhibiting the overexpression and activity of NIK.
Effectively inhibiting the overactivity of NIK and alleviating the symptoms of related diseases such as inflammation, immune response disorders and cancer, providing potential therapeutic targets.
Smart Images

Figure BDA0004953709620000041 
Figure BDA0004953709620000051 
Figure BDA0004953709620000061
Abstract
Description
[0001] This application is a divisional application of the invention patent application with the application date of May 29, 2020, application number 202080057418.X, and invention name “Small molecule inhibitors of NF-κB-induced kinase”. Technical Field
[0002] NF-κB-inducing kinase (referred to as NIK, also known as MAP3K14) is a regulator and driver of the non-classical NIK cascade and therefore represents an attractive target for therapeutic intervention. The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds. It is envisioned that these compounds and pharmaceutical compositions can be used to prevent or treat diseases such as cancer (such as B-cell malignancies, including leukemias, lymphomas, and myelomas), inflammatory disorders, autoimmune disorders, immunodermatological disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes. The present invention also relates to methods for preventing or treating such diseases. Background Art
[0003] NIK is a serine / threonine kinase transcription factor that promotes the expression of various genes involved in immune response disorders, cell proliferation disorders, adhesion, apoptosis, and carcinogenesis. Due to this immune system regulatory role, NIK inhibition blocks several downstream pathways that produce inflammatory molecules. Clinical validation using biologics has confirmed the key role of several NIK-dependent pathways in autoimmune diseases. See, for example, SV Navarra et al., The Lancet, 2011, Vol. 377, No. 9767: pp. 721-731. NIK-dependent transcriptional activation is a tightly controlled signaling pathway that involves sequential events including phosphorylation and protein degradation. In the NIK activation pathway, known as the non-canonical pathway, activation is achieved through phosphorylation of the catalytic complex subunit IKKα, leading to partial proteolysis of the gene product p100, thereby releasing the DNA-binding protein p52, which then heterodimerizes with another DNA-binding protein, RelB, translocates to the nucleus, and mediates gene expression. The non-classical pathway is activated by ligands such as CD40 ligand, B-cell activating factor (BAFF), lymphotoxin beta receptor ligand, TNF-related weak inducer of apoptosis (TWEAK) cytokines, and receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11). NIK has been shown to be essential for activation of the pathway by these ligands (S.-C. Sun, Nat Rev Immunol., 2017, Vol. 17, No. 9, pp. 545-558). Due to its role, NIK expression is strictly regulated. Under normal non-stimulated conditions, NIK protein levels are very low. This is due to its interaction with baculoviral IAP repeat-containing protein 3 (BIRC3, also known as CIAP2) and a series of TNF receptor-associated factors (TRAF2 and TRAF3), which are ubiquitin ligases that lead to NIK degradation. It is believed that when the non-classical pathway is stimulated by a ligand under pathological / abnormal conditions, the activated receptor now competes for TRAF, dissociates the TRAF-BIRC3-NIK complex, and thereby increases NIK levels (for a more detailed analysis of this background, see, for example, S.-C. Sun (cited above) and Thu and Richmond, Cytokine Growth FR, 2010, Vol. 21, pp. 213-226). As described above, NIK plays a role in promoting immune response disorders, cell proliferation disorders, adhesion, apoptosis, and carcinogenesis, and therefore, increased NIK levels are undesirable, and one approach to alleviating or eliminating the adverse effects associated with such increases is NIK inhibition.
[0004] BAFF / BAFF-R is a clinically validated therapeutic target, and its inhibition is considered to be beneficial for the treatment of systemic lupus erythematosus (SLE). Belimumab (anti-BAFF antibody) has been approved for the treatment of seropositive SLE patients (SV Navarra et al., The Lancet, 2011, Vol. 377, No. 9767: pp. 721-731). The CD40L / CD40 pathway plays a key role in T-dependent B cell activation, dendritic cell maturation, and tissue inflammation / immunity (R. Elgueta et al., Immunol. Rev., 2009, Vol. 229, No. 1: pp. 152-172). Anti-CD40L antibodies have shown promising efficacy in a Phase 2 clinical study in patients with SLE (PI Sidiropoulos and DT Boumpas, Lupus, May 2004, Vol. 13, No. 5, pp. 391-397). Mice lacking NIK (R. Shinkura et al., Nature Genetics, 1999, Vol. 22, No. 1: pp. 74-77; HD Brightbill et al., J Immunol., 2015, Vol. 195, No. 3: pp. 953-964) or conditional knockout of NIK (HD Brightbill et al., J Immunol., 2015, Vol. 195, No. 3: pp. 953-964) or human patients carrying NIK gene mutations (KL Willmann et al., Nature Comm., 2014, Vol. 5, p. 5360) showed that the lack of non-classical NIK activation pathways such as BAFF and CD401 pathways, reduced B lymphocytes in peripheral blood and lymphoid organs, and lower T cell-dependent antibody responses all support NIK as a therapeutic target for SLE.
[0005] NIK has been described as "important in the immune and bone-destructive components of inflammatory arthritis and represents a possible therapeutic target for these diseases." K. Aya et al. (J. Clin. Invest., 2005, Vol. 115, pp. 1848-1854). Mice lacking functional NIK have no peripheral lymph nodes, have defective B cells and T cells, and have impaired receptor activators for NIK ligand-stimulated osteoclastogenesis. K. Aya et al. (J. Clin. Invest., 2005, Vol. 115, pp. 1848-1854) used NIK- / - mice to study the role of NIK in a mouse model of inflammatory arthritis. It is reported that the serum transfer arthritis model is initiated by preformed antibodies and only requires intact neutrophils and complement systems in the recipient. Although NIK- / - mice have inflammation comparable to NIK+ / + controls, Ada et al. (as cited above) revealed a significant reduction in periarticular osteoclastogenesis and reduced bone erosion. In contrast, NIK- / - mice are completely resistant to antigen-induced arthritis (AIA), which requires intact antigen presentation and lymphocyte function, but does not require lymph nodes. In addition, the transfer of NIK+ / + splenocytes or T cells to Rag2- / - mice confers susceptibility to AIA, while the transfer of NIK- / - cells has no such effect. NIK- / - mice are also resistant to a genetic, spontaneous form of arthritis that is produced in mice expressing both the KRN T cell receptor and H-2g7. Transgenic mice were used with OC lineage expression of NIK lacking its TRAF3 binding domain (NT3) to demonstrate that constitutive activation of NIK drives enhanced osteoclastogenesis and bone resorption under basal conditions and in response to inflammatory stimuli. See Aya et al., cited above. Furthermore, it has been concluded that “constitutive activation of NIK drives enhanced osteoclastogenesis and bone resorption both under basal conditions and in response to inflammatory stimuli.” (C. Yang et al., PLoS ONE, 2010, Vol. 5, No. 11, p. e15383, doi:10.1371 / journal.pone.0015383).
[0006] It has also been hypothesized that manipulating NIK levels in T cells may have therapeutic value. Reducing NIK activity in T cells may significantly improve autoimmune and allogeneic responses, such as GvHD (graft-versus-host disease) and transplant rejection, without severely damaging the immune system like inhibitors of another NIK activation pathway, called the classical pathway (S. E. Murray et al., "NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice," J. Clin. Invest., 2011, vol. 121, no. 12, pp. 4775-4786) (providing data described as "suggesting that tight regulation of [NIK] is crucial for avoiding autoimmunity"). (The classical NIK activation pathway relies on the inducible degradation of IκB kinases, particularly IκBα, leading to the nuclear translocation of various NF-κB complexes, primarily the p50 / RelA dimer. The degradation of IκBα is mediated by its phosphorylation by IκB kinase (IKK), a trimeric complex composed of two catalytic subunits, IKKα and IKKβ, and one regulatory subunit, IKKγ (also known as essential regulator of NF-κB or NEMO). In the non-classical NIK activation pathway, the RelB / p52 NF-κB complex is activated using a mechanism that relies on inducible processing of p100 rather than degradation of IκBα. See, e.g., S.-C. Sun, Cell Res., January 2011, Vol. 21, No. 1, pp. 71-85).
[0007] NIK is also a ligand in other BAFF, CD40L or lymphotoxin beta receptor driven autoimmune disorders such as Sjögren's syndrome (J. Groom et al., J. Clin. Invest., 2002, Vol. 109, No. 1, pp. 59-68; proliferative lupus nephritis (DT Boumpas et al., Arthritis & Rheumatism, 2003, Vol. 48, No. 3, pp. 719-727), multiple sclerosis (J. Tan et al., J. Neuroimmunol, 1999, Vol. 97, No. 1-2, pp. 77-85; J. Krumbholz et al., J. Exp. Med., 2005, Vol. 201, No. 2, pp. 195-200) and pemphigus vulgaris (Z. Liu et al., J. Invest. Dermatol., 2006, Vol. 126, No. 1, pp. 11-13). Summary of the Invention
[0008] Embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof
[0009]
[0010] in
[0011] R 1 is H or -CH3;
[0012] R 2 is H or -CH3;
[0013] R 3 is H, -C1-C5 alkyl, -OCH3 or -O-C1-C3 haloalkyl;
[0014] R 4 is H or -CH3;
[0015] part for
[0016]
[0017] R aa is H or -CH3;
[0018] R bb is H, -CH3 or -CF3;
[0019] R cc -CH3, -CD3 or -CH2CF3; part for
[0020]
[0021] E is N or CH;
[0022] F is O, S, NH or NCH3;
[0023] R a is H or -CH3;
[0024] R b is H, D, -OH, F, -C1-C5 alkyl, -CH2OCH3, -C1-C5 haloalkyl, -NH2, cyclopropyl or -CH2OH;
[0025] R c is H, D or -CH3;
[0026] R d is H, -CN, -CF3, -C1-C5 alkyl, -C3-C6 cycloalkyl, -O-C1-C3 alkyl, -N(R 6 )R 7 ,
[0027]
[0028] in
[0029] R 6 is H or -C1-C3 alkyl;
[0030] R 7 is H, -C1-C3 alkyl, -SO2CH3, -COCH3, -C1-C4 haloalkyl or -CH2CN, or R 6 and R 7 Together with the nitrogen to which they are attached to form part Where m is 0 or 1, and p is 0 or 1;
[0031] R 8 is H, F or -C1-C3 alkyl;
[0032] R 9 is H, F or -C1-C3 alkyl;
[0033] R e is H, -CD3, Br, -C1-C5 alkyl, -C3-C6 cycloalkyl,
[0034]
[0035] 1 to 3 R g -C1-C5 alkyl substituted by a group, wherein R g is -NH2 or F;
[0036] R 10 H or F;
[0037] R 11 H or F;
[0038] R f H, -CH3 or
[0039] R h -CH3, -NH2 or
[0040] R i For H, -CH3, -CN, Br,
[0041] R j -NH2 or
[0042] R k is H, -CF3, I, Cl, Br, -CN, -C1-C6 alkyl,
[0043]
[0044] R 12 is H or -CH3;
[0045] R 13 is H, -CH3, -CH2(C)(CH3)2OH, -(CH2)3CN or -(CH2)2NH2;
[0046] R 14 is H or -CH3;
[0047] R l H, -C1-C4 alkyl, -CF3,
[0048] R m is H or -CH3;
[0049] R n is -NH2;
[0050] R o is H or -CH3;
[0051] R p is H or -CH3;
[0052] R q is H, -CN, F, Cl, -OCH3, -CF3 or -CH3; and
[0053] R s -NH2 or
[0054] The prerequisite is that part And each R 1 、R 2 、R 3 and R 4 When H, part
[0055] An exemplary embodiment of the compound of formula (I) is compound
[0056] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0057] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0058] (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0059] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0060] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0061] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0062] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0063] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0064] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0065] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0066] (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0067] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0068] (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0069] (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0070] (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0071] (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0072] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0073] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0074] (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0075] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0076] (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0077] (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0078] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0079] (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0080] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0081] (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0082] (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0083] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0084] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0085] (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0086] (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0087] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0088] 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]cyclopentanol;
[0089] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0090] 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-methyl-but-3-yn-2-ol;
[0091] (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0092] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0093] (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0094] (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0095] (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0096] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0097] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0098] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0099] (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0100] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0101] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0102] (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0103] (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0104] (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0105] (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0106] (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0107] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0108] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0109] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0110] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidin-4(3H)-one;
[0111] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0112] (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0113] (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0114] (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0115] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0116] (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0117] (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0118] (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0119] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0120] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0121] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0122] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0123] (R)-4-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0124] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0125] (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0126] (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0127] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0128] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0129] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0130] (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0131] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0132] (R)-3-[2-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0133] (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0134] (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0135] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0136] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0137] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0138] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[0139] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol;
[0140] (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0141] (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0142] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0143] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0144] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0145] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0146] (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0147] (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0148] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0149] (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0150] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0151] (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0152] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0153] (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0154] (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0155] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonitrile;
[0156] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0157] (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0158] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0159] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0160] (R)-4-[3-(4-Aminoquinazolin-6-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0161] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0162] 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine;
[0163] (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0164] (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0165] (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0166] (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0167] (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0168] (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0169] (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0170] (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0171] (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0172] (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0173] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonitrile;
[0174] (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0175] (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0176] (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0177] (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0178] (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl-propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0179] (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0180] (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0181] (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile;
[0182] (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0183] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidine-5-carboxylic acid phenyl ester;
[0184] (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0185] (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0186] (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[0187] (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[0188] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0189] (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0190] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0191] (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0192] (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0193] (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0194] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0195] (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin-5-yl]pyrazol-1-yl]butanenitrile;
[0196] (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0197] (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0198] (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0199] (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0200] (R)-3-[2-[3-[8-amino-5-(1-piperidinylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0201] (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0202] (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pyridinyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0203] (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0204] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0205] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0206] (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0207] (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0208] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0209] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0210] (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0211] (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0212] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[0213] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[0214] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0215] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0216] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0217] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[0218] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[0219] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0220] rac-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol;
[0221] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[0222] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[0223] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0224] (R)-tert-Butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate;
[0225] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0226] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0227] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0228] (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0229] (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0230] (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0231] (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0232] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0233] (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0234] (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0235] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[0236] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[0237] (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0238] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0239] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0240] 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]cyclopentanol;
[0241] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0242] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0243] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0244] (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0245] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[0246] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[0247] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[0248] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[0249] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0250] 1-allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[0251] rac-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[0252] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[0253] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[0254] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0255] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[0256] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[0257] rac-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol;
[0258] (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0259] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[0260] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[0261] (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0262] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-methoxy-1-methylpyrrolidin-2-one;
[0263] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[0264] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[0265] (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0266] (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0267] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[0268] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0269] (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0270] (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0271] (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0272] (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0273] (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one;
[0274] (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0275] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0276] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one;
[0277] (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0278] ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0279] (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido[5,4-c]azepine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0280] (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0281] (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0282] (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0283] (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0284] (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-ylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0285] (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0286] (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0287] (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0288] (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0289] (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0290] (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0291] (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0292] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0293] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetamide;
[0294] (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0295] (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino)acetonitrile;
[0296] (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0297] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidine-3-carbonitrile;
[0298] (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0299] (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0300] (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl)azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0301] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methylazetidine-3-carboxamide;
[0302] (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0303] (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0304] (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0305] (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0306] (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile;
[0307] (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0308] (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0309] (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0310] (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0311] (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0312] (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0313] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)acetamide;
[0314] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)acetamide;
[0315] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0316] (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0317] (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0318] (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0319] (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0320] (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0321] (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0322] (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0323] (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0324] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)methanesulfonamide;
[0325] (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0326] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0327] (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0328] (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0329] (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0330] (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0331] (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0332] (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0333] (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0334] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile;
[0335] (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0336] (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0337] (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0338] (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0339] (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0340] (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0341] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0342] (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0343] (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0344] (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0345] (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0346] (3R,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0347] (3R,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0348] (3S,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0349] (3S,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0350] (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0351] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0352] (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0353] (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0354] (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0355] (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0356] (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0357] (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0358] (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0359] (R)-3-[2-[3-[4-amino-8-(cyclopropyloxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0360] (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazol-4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0361] (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0362] (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro[2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0363] (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0364] (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0365] (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0366] (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0367] (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0368] (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0369] (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0370] (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin-1-yl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0371] (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0372] (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0373] (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0374] (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one; and
[0375] or a pharmaceutically acceptable salt thereof.
[0376] Embodiments of the present invention are directed to compounds, pharmaceutical compositions comprising these compounds, methods of making and purifying these compounds, methods of using these compounds as NIK inhibitors, and methods of using these compounds for treating disease states, disorders, and conditions mediated by NIK.
[0377] Additional embodiments of the present invention are methods of using the compounds of the present invention to treat a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NIK.
[0378] Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention. DETAILED DESCRIPTION
[0379] As used herein, the terms "including," "containing," and "comprising" are used in their open, non-limiting sense.
[0380] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, regardless of whether the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value, and it is also intended to refer to the approximate value of these given values that can be reasonably inferred based on ordinary skills in the art, including equivalent values and approximate values of these given values caused by experimental and / or measurement conditions.
[0381] Unless otherwise specified in a specific example, the term "alkyl" refers to a straight or branched chain alkyl group having 1 to 8 carbon atoms in the chain. Examples of alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that would be considered equivalent to any of the foregoing examples based on the ordinary skill in the art and the teachings provided herein. "C1-C4 alkyl" refers to a straight or branched chain alkyl group having 1 to 4 carbon atoms in the chain.
[0382] The term "halogen" denotes chlorine, fluorine, bromine or iodine.
[0383] The term "haloalkyl" refers to a linear or branched alkyl group having 1 to 6 carbon atoms in the chain, optionally substituted with halogen for one or more H. As used herein, the term "C1-C4 haloalkyl" refers to a linear or branched alkyl group having 1 to 4 carbon atoms in the chain, optionally substituted with halogen for one or more H. Examples of "haloalkyl" groups include trifluoromethyl (CF3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), trifluoroethyl (CH2CF3), tetrafluorotrifluoromethylethyl (CF(CF3)2), and groups that would be considered equivalent to any of the foregoing examples based on ordinary skill in the art and the teachings provided herein.
[0384] The term "cycloalkyl" refers to a saturated, monocyclic, fused polycyclic or spiropolycyclic carbocycle having from 3 to 10 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities in the form of appropriate bonding moieties, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
[0385] The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted with one or more substituents. If the term "substituted" is used to describe a structural system, it means that substitution occurs at any valence-allowed position on that system.
[0386] Any formula given herein is intended to represent compounds having the structure shown in the given structural formula and certain variations or forms. Specifically, the compounds of any formula given herein may have asymmetric centers and therefore may exist in different enantiomeric forms. All optical isomers and stereoisomers of compounds of the general formula and mixtures thereof are considered to be within the scope of such formulas. The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds may be prepared as individual (R)- or (S)-stereoisomers or as mixtures thereof. Therefore, unless otherwise expressly indicated, any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof.
[0387] Some examples contain chemical structures that include the terms (R*) or (S*). When (R*) or (S*) is used in the name of a compound or in the chemical representation of a compound, it is intended to indicate that the compound is a single isomer at that stereocenter, however, the absolute configuration at that stereocenter has not been determined. Thus, a compound designated as (R*) refers to a compound that is a single isomer at that stereocenter, with an absolute configuration of either (R) or (S). A compound designated as (S*) refers to a compound that is a single isomer at that stereocenter, with an absolute configuration of either (R) or (S). In cases where the absolute stereochemistry has been determined, (R) and (S) are used to name the structure. Use of the term (R,S) or "racemic" in a compound name indicates that the compound is a racemate.
[0388] Reference herein to a compound is intended to include reference to any of: (a) the compound in the form actually recited, and (b) the compound in any form in which the compound is present in the medium in which the compound is present. For example, reference herein to a compound such as R-COOH encompasses reference to any of: R-COOH(s), ... (sol) and R-COO - (sol) In this example, R-COOH(s) refers to a solid compound, which may be in the form of, for example, a tablet or some other solid pharmaceutical composition or formulation; R-COOH(sol) refers to the undissociated form of the compound in a solvent; and R-COO - (sol) Refers to the dissociated form of a compound in a solvent, such as the dissociated form of a compound in an aqueous environment, whether such dissociated form is derived from R-COOH, a salt thereof, or any other entity that produces R-COO- upon dissociation in the medium under consideration. In another example, a statement such as "exposing an entity to a compound of formula R-COOH" refers to exposing the entity to one or more forms of the compound R-COOH present in the medium in which the exposure occurs. In yet another example, a statement such as "reacting an entity with a compound of formula R-COOH" refers to reacting (a) such entity (being one or more chemically related forms of such entity present in the medium in which the reaction occurs) with (b) one or more chemically related forms of the compound R-COOH present in the medium in which the reaction occurs. In this regard, if the entity is, for example, in an aqueous environment, it is understood that the compound R-COOH is in the same medium and therefore the entity is being exposed to a compound such as R-COOH. (aq) and / or R-COO - (aq), wherein the subscript "(aq)" represents "aqueous" according to its conventional meaning in chemistry and biochemistry. In these naming examples, a carboxylic acid functional group is selected; however, this selection is not intended to be limiting, but is merely illustrative. It should be understood that similar examples can be provided with other functional groups, including but not limited to hydroxyl groups, basic nitrogen members (such as those in amines), and any other groups that interact or transform in a medium containing the compound in a known manner. Such interactions and transformations include but are not limited to dissociation, association, tautomerism, solvolysis including hydrolysis, solvation including hydration, protonation, and deprotonation. No further examples are provided herein in this regard, as these interactions and transformations in a given medium are known to any person of ordinary skill in the art.
[0389] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by atoms having a selected atomic mass or mass number in enriched form. Examples of isotopes that can be incorporated into the compounds of the invention in excess of natural abundance include: isotopes of hydrogen, carbon, nitrogen, and oxygen, such as 2 H (or D), 3 H. 11 C. 13 C. 14 C. 15 N. 18 O and 17 O. Such isotope-labeled compounds can be used for metabolic studies (e.g., using 14 C), reaction kinetic studies (using, for example, deuterium (i.e., D or 2 H); or tritium (i.e., T or 3 H)), detection or imaging techniques [such as positron emission tomography (PET) or single photon emission computed tomography (SPECT)], including drug or substrate tissue distribution determination, or in radiotherapy of patients. Specifically, 18 F or 11 Compounds labeled with C can be used for PET or SPECT studies. In addition, substitution with heavier isotopes such as deuterium can provide certain therapeutic advantages resulting from greater metabolic stability, such as increased local in vivo half-life or reduced required dosage. Isotopically labeled compounds of the invention can generally be prepared by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents to carry out the procedures disclosed in the "Schemes" or "Examples and Preparations" described below.
[0390] When the same multiple substituents are assigned to multiple groups, the specific individual substituent assignments assigned to each of such groups are intended to be selected independently of the specific individual substituent assignments to the remaining groups. By way of example, but not limitation, if each of the groups Q and R can be H or F, then the selection of H or F for Q is made independently of the selection of H or F for R, so that unless otherwise expressly stated, the selection of the assignment for Q does not determine or determine the selection of the assignment for R, or conversely, the selection of the assignment for R does not determine or determine the selection of the assignment for Q. In this regard, exemplary claim formulations are to be understood as "each of Q and R is independently H or F," or "each of Q and R is independently selected from H and F."
[0391] "Tautomers" refer to compounds that are interchangeable forms of a particular compound structure, with variations in the positions of hydrogens and electrons. Thus, two structures with H members in different positions can be in equilibrium while satisfying the rules of valence. For example, enols and ketones are tautomers because they readily convert to each other upon treatment with acid or base. When referring to any formula given herein that contains at least one tautomer, unless expressly stated otherwise, such given formula is intended to encompass all relevant tautomers.
[0392] When referring to any formula given herein, for a given variable, selecting a particular part from a list of possible species is not intended to limit the selection of the same species when the variable appears elsewhere. In other words, unless otherwise indicated, when a variable appears more than once, selecting that species from a given list is independent of selecting that species for the same variable elsewhere in the formula.
[0393] With respect to the first example of the substituent term, if the substituent S 1 实施例 is one of S1 and S2, and the substituent S 2 实施例 is one of S3 and S4, then these designations refer to the embodiments of the present invention resulting from the following selections: S 1 实施例 is S1 and S 2 实施例 S3; S 1 实施例 is S1 and S 2 实施例 S4; S 1 实施例 is S2 and S 2 实施例 S3; S 1 实施例 is S2 and S 2 实施例S4; and equivalent designations for each of these options. Therefore, for the sake of simplicity, the shorter term "S 1 实施例 is one of S1 and S2, and S 2 实施例 One of S3 and S4" or "S 1 实施例 is S1 or S2, and S 2 实施例 is S3 or S4", but is not limiting. The first example of substituent terminology stated above in general terms is intended to illustrate the different substituent assignments described herein.
[0394] Furthermore, when more than one designation is given for any member or substituent, embodiments of the invention include various groupings that can be made independently from the listed designations, and equivalents thereof. With respect to the second example of substituent terminology, if it is described herein that a substituent S 实施例 is one of S1, S2 and S3, then the enumeration refers to the following embodiments of the present invention: S 实施例 S1; S 实施例 S2; S 实施例 S3; S 实施例 is one of S1 and S2; S 实施例 is one of S1 and S3; S 实施例 is one of S2 and S3; S 实施例 is one of S1, S2 and S3; and S 实施例 For the sake of simplicity, the shorter term "S 实施例 is one of S1, S2 and S3" or "S 实施例 The second example of substituent terminology stated above in a generic manner is intended to illustrate the multiple substituent assignments described herein.
[0395] The term "C i -C j "(j>i), when applied herein to a group of substituents, is intended to refer to embodiments of the invention wherein each and every number of carbon members from i to j (inclusive) is independently realized. By way of example, the terms C1-C3 independently refer to an embodiment having one carbon member (C1), an embodiment having two carbon members (C2), and an embodiment having three carbon members (C3). For example, the term C i -C j Alkyl refers to an aliphatic chain, whether straight or branched, in which the total number of carbon members N satisfies i≤N≤j, and i>j.
[0396] A "pharmaceutically acceptable salt" is a salt of a compound (such as the compounds of the present invention) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to a subject. See generally: SM Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., Vol. 66: 1-19 (1977); Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, eds., Wiley-VCH and VHCA, Zurich, 2002; and GS Paulekuhn et al., "Pharmaceutical ingredientsalt selection based on analysis of the Orange Book database," J. Med. Chem., Vol. 50: 6665-6672 (2007). The compounds of the present invention may possess sufficiently acidic groups, sufficiently basic groups, or both types of functional groups and accordingly react with a variety of inorganic or organic bases and inorganic and organic acids to form pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, octanoate, acrylate, formate, isobutyrate, hexanoate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
[0397] If the compound of the present invention contains at least one basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, by treating the free base with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid and phosphoric acid; or an organic acid such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, benzoic ... Cinnamic acid, pyranosidic acid (such as glucuronic acid or galacturonic acid), α-hydroxy acid (such as mandelic acid, citric acid or tartaric acid), amino acid (such as aspartic acid or glutamic acid), aromatic acid (such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid or cinnamic acid), sulfonic acid (such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid), any compatible mixture of acids such as those given as examples herein, and any other acids and mixtures thereof deemed equivalent or acceptable substitutes according to the ordinary skill in the art.
[0398] Embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof
[0399]
[0400] in
[0401] R 1 is H or -CH3;
[0402] R 2 is H or -CH3;
[0403] R 3 is H, -C1-C5 alkyl, -OCH3 or -O-C1-C3 haloalkyl;
[0404] R 4 is H or -CH3;
[0405] part for
[0406]
[0407] R aa is H or -CH3;
[0408] R bb is H, -CH3 or -CF3;
[0409] R cc -CH3, -CD3 or -CH2CF3; part for
[0410]
[0411] E is N or CH;
[0412] F is O, S, NH or NCH3;
[0413] R a is H or -CH3;
[0414] R b is H, D, -OH, F, -C1-C5 alkyl, -CH2OCH3, -C1-C5 haloalkyl, -NH2, cyclopropyl or -CH2OH;
[0415] R c is H, D or -CH3;
[0416] R d is H, -CN, -CF3, -C1-C5 alkyl, -C3-C6 cycloalkyl, -O-C1-C3 alkyl, -N(R 6 )R 7 ,
[0417]
[0418] R 6 is H or -C1-C3 alkyl;
[0419] R 7 is H, -C1-C3 alkyl, -SO2CH3, -COCH3, -C1-C4 haloalkyl or CH2CN;
[0420] or R 6 and R 7 Together with the nitrogen to which they are attached to form part Where m is 0 or 1, and p is 0 or 1;
[0421] R 8 is H, F or -C1-C3 alkyl;
[0422] R 9 is H, F or -C1-C3 alkyl;
[0423] R e is H, -CD3, Br, -C1-C5 alkyl, -C3-C6 cycloalkyl,
[0424]
[0425] 1 to 3 R g -C1-C5 alkyl substituted by a group, wherein R g is -NH2 or F;
[0426] R 10 H or F;
[0427] R 11 H or F;
[0428] R f H, -CH3 or R h -CH3, -NH2 or R i For H, -CH3, -CN, Br, R j -NH2 or R k is H, -CF3, I, Cl, Br, -CN, -C1-C6 alkyl,
[0429]
[0430] R 12 is H or -CH3;
[0431] R 13 is H, -CH3, -CH2(C)(CH3)2OH, -(CH2)3CN or -(CH2)2NH2;
[0432] R 14 is H or -CH3;
[0433] R l H, -C1-C4 alkyl, -CF3, R m is H or -CH3;
[0434] R n is -NH2;
[0435] R o is H or -CH3;
[0436] R p is H or -CH3;
[0437] R q is H, -CN, F, Cl, -OCH3, -CF3 or -CH3; and
[0438] R s -NH2 or
[0439] The prerequisite is that when the part And R 1 、R 2 、R 3 and R 4 When H, the part
[0440] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0441] part for
[0442]
[0443] And part for
[0444]
[0445] The prerequisite is that when the part And R 1 、R 2 、R 3 and R 4 When H, the part
[0446] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0447] part for
[0448]
[0449] And part for
[0450]
[0451] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0452]
[0453] And part for
[0454]
[0455] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0456] part for
[0457]
[0458] And part for
[0459]
[0460] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 H; R 2 H; R 3 H; R 4 is H;
[0461] part for and
[0462] part for
[0463] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 H; R 2 H; R 3 is H or -C1-C5 alkyl; R 4 is H;
[0464] part for and
[0465] part for
[0466] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0467] R 1 H; R 2 H; R 3 is H or -C1-C5 alkyl; R 4 is H;
[0468] part for and
[0469] part for
[0470] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0471] R 1 H; R 2 H; R 3 H; R 4 is H;
[0472] part for and
[0473] part for
[0474] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0475] R 1 H; R 2 H; R 3 H; R 4 is H;
[0476] part for R cc is -CH3;
[0477] part for And R b is -CH3.
[0478] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0479] R 1 H; R 2 H; R 3 H; R 4 is H;
[0480] part for R cc is -CD3;
[0481] part for And R b is -CH3.
[0482] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0483]
[0484] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0485]
[0486] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0487]
[0488] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0489]
[0490] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0491] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0492] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0493]
[0494] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0495] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0496] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0497] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0498] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0499] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0500] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0501] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0502] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0503] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0504] part for
[0505]
[0506] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0507]
[0508] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0509]
[0510] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0511] part for
[0512] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0513] part for
[0514] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0515] part for
[0516] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein
[0517] part for
[0518] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0519] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0520] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0521] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0522] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0523] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0524] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0525] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0526] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0527] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for
[0528] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0529] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0530] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0531] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0532] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0533] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0534] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0535] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0536] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0537] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for And part for
[0538] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for And R 3 For H.
[0539] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 is H, and R e For H.
[0540] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R e is H, and R d N(R 6 )R 7 .
[0541] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R e H, R d N(R 6 )R 7 , and R b For CH3.
[0542] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 is H or C1-C3 alkyl, and R 7 is H or C1-C3 alkyl.
[0543] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 is a C1-C3 alkyl group, and R 7 It is a C1-C3 alkyl group.
[0544] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R3 is H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 is H, and R 7 For H.
[0545] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for , R3 is H, R a H, R e H, R d N(R 6)R 7 , R b is CH3, and R 6 and R 7 Together with the nitrogen to which it is attached, it forms part Where m is 0 or 1, and p is 0 or 1.
[0546] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 and R 7 Together with the nitrogen to which it is attached, it forms part Where m is 0, and p is 0;
[0547] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 and R 7 Together with the nitrogen to which it is attached, it forms part Where m is 1 and p is 0.
[0548] Another exemplary embodiment of the present invention is a compound of formula (I) and a pharmaceutically acceptable salt thereof, wherein some for part for R 3 H, R a H, R e H, R d N(R 6 )R 7 , R b CH3, R 6 and R 7 Together with the nitrogen to which it is attached, it forms part Where m is 1 and p is 1.
[0549] An exemplary embodiment of the compound of formula (I) is compound
[0550] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0551] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0552] (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0553] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0554] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0555] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0556] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0557] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0558] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0559] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0560] (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0561] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0562] (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0563] (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0564] (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0565] (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0566] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0567] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0568] (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0569] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0570] (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0571] (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0572] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0573] (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0574] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0575] (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0576] (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0577] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0578] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0579] (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0580] (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0581] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0582] 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]cyclopentanol;
[0583] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0584] 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-methyl-but-3-yn-2-ol;
[0585] (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0586] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0587] (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0588] (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0589] (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0590] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0591] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0592] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0593] (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0594] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0595] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0596] (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0597] (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0598] (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0599] (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0600] (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0601] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0602] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0603] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0604] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidin-4(3H)-one;
[0605] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0606] (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0607] (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0608] (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0609] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0610] (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0611] (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0612] (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0613] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0614] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0615] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0616] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0617] (R)-4-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0618] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0619] (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0620] (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0621] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0622] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0623] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0624] (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0625] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0626] (R)-3-[2-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0627] (R)-4-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0628] (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0629] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0630] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0631] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0632] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[0633] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol;
[0634] (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0635] (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0636] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0637] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0638] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0639] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0640] (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0641] (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0642] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0643] (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0644] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0645] (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0646] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0647] (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0648] (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0649] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonitrile;
[0650] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0651] (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0652] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0653] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0654] (R)-4-[3-(4-Aminoquinazolin-6-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0655] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0656] 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine;
[0657] (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0658] (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0659] (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0660] (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0661] (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0662] (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0663] (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0664] (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0665] (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0666] (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0667] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonitrile;
[0668] (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0669] (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0670] (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0671] (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0672] (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl-propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0673] (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0674] (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0675] (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile;
[0676] (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0677] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidine-5-carboxylic acid phenyl ester;
[0678] (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0679] (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0680] (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[0681] (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[0682] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0683] (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0684] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0685] (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0686] (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0687] (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0688] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0689] (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin-5-yl]pyrazol-1-yl]butanenitrile;
[0690] (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0691] (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0692] (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0693] (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0694] (R)-3-[2-[3-[8-amino-5-(1-piperidinylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0695] (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0696] (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pyridinyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0697] (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0698] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0699] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0700] (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0701] (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0702] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0703] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0704] (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0705] (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0706] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[0707] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[0708] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0709] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0710] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0711] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[0712] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[0713] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0714] rac-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol;
[0715] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[0716] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[0717] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0718] (R)-tert-Butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate;
[0719] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0720] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0721] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0722] (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0723] (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0724] (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0725] (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0726] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0727] (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0728] (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0729] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[0730] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[0731] (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0732] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0733] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0734] 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]cyclopentanol;
[0735] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0736] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0737] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0738] (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0739] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[0740] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[0741] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[0742] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[0743] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0744] 1-allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[0745] rac-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[0746] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[0747] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[0748] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[0749] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[0750] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[0751] rac-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol;
[0752] (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0753] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[0754] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[0755] (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0756] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-methoxy-1-methylpyrrolidin-2-one;
[0757] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[0758] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[0759] (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0760] (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0761] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[0762] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0763] (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0764] (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0765] (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0766] (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0767] (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one;
[0768] (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0769] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0770] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one;
[0771] (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0772] ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0773] (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido[5,4-c]azepine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0774] (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0775] (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0776] (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0777] (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0778] (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-ylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0779] (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0780] (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0781] (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0782] (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0783] (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0784] (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0785] (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0786] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0787] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetamide;
[0788] (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0789] (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino)acetonitrile;
[0790] (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0791] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidine-3-carbonitrile;
[0792] (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0793] (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0794] (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl)azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0795] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methylazetidine-3-carboxamide;
[0796] (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0797] (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0798] (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0799] (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0800] (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile;
[0801] (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0802] (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0803] (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0804] (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0805] (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0806] (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0807] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)acetamide;
[0808] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)acetamide;
[0809] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0810] (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0811] (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0812] (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0813] (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0814] (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0815] (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0816] (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0817] (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[0818] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)methanesulfonamide;
[0819] (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0820] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0821] (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[0822] (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0823] (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0824] (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0825] (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0826] (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0827] (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0828] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile;
[0829] (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0830] (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0831] (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0832] (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0833] (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0834] (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0835] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0836] (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0837] (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0838] (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0839] (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0840] (3R,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0841] (3R,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0842] (3S,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0843] (3S,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[0844] (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0845] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0846] (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0847] (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0848] (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0849] (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0850] (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0851] (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0852] (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0853] (R)-3-[2-[3-[4-amino-8-(cyclopropyloxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0854] (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazol-4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0855] (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0856] (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro[2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0857] (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0858] (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0859] (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0860] (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0861] (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0862] (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0863] (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0864] (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin-1-yl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0865] (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0866] (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0867] (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[0868] (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one; and
[0869] or a pharmaceutically acceptable salt thereof.
[0870] An exemplary embodiment of the compound of formula (I) is compound
[0871] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0872] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0873] (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0874] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0875] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0876] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0877] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0878] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0879] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0880] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0881] (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0882] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0883] (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0884] (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0885] (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0886] (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0887] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0888] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0889] (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0890] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0891] (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0892] (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0893] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0894] (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0895] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0896] (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0897] (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[0898] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0899] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0900] (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0901] (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0902] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0903] 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]cyclopentanol;
[0904] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0905] 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-methyl-but-3-yn-2-ol;
[0906] (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0907] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0908] (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0909] (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0910] (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0911] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0912] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0913] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0914] (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0915] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0916] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0917] (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one;
[0918] (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0919] (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0920] (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0921] (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0922] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0923] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0924] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0925] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidin-4(3H)-one;
[0926] (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0927] (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0928] (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0929] (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0930] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0931] (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0932] (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0933] (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0934] (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0935] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0936] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0937] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0938] (R)-4-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0939] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0940] (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0941] (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0942] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0943] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0944] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0945] (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[0946] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0947] (R)-3-[2-[3-(1-amino-7-isoquinolinyl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0948] (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0949] (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0950] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[0951] (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0952] (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4-methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0953] (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[0954] (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol;
[0955] (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0956] (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0957] (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[0958] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0959] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0960] (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0961] (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[0962] (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidin-2-one;
[0963] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0964] (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0965] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0966] (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0967] (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0968] (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0969] (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0970] (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonitrile;
[0971] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0972] (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0973] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0974] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[0975] (R)-4-[3-(4-Aminoquinazolin-6-yl)phenyl]-2-thiazol-2-yl-but-3-yn-2-ol;
[0976] (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[0977] 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine;
[0978] (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[0979] (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0980] (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0981] (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0982] (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0983] (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0984] (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0985] (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0986] (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0987] (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0988] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonitrile;
[0989] (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0990] (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0991] (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[0992] (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0993] (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl-propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0994] (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0995] (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0996] (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile;
[0997] (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[0998] (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidine-5-carboxylic acid phenyl ester;
[0999] (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1000] (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1001] (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[1002] (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone;
[1003] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1004] (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1005] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1006] (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1007] (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[1008] (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1009] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1010] (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin-5-yl]pyrazol-1-yl]butanenitrile;
[1011] (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1012] (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1013] (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1014] (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[1015] (R)-3-[2-[3-[8-amino-5-(1-piperidinylmethyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1016] (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[1017] (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pyridinyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1018] (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1019] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1020] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1021] (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1022] (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1023] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1024] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1025] (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol;
[1026] (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1027] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[1028] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol;
[1029] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1030] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1031] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1032] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[1033] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol;
[1034] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol;
[1035] rac-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol;
[1036] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[1037] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol;
[1038] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1039] (R)-tert-Butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate;
[1040] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1041] (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1042] (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1043] (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1044] (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1045] (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1046] (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1047] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1048] (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1049] (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1050] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[1051] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol;
[1052] (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1053] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[1054] (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol;
[1055] 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]cyclopentanol;
[1056] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[1057] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[1058] (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1059] (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1060] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[1061] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol;
[1062] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[1063] (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(4-(trifluoromethyl)thiazol-2-yl)but-3-yn-2-ol;
[1064] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1065] 1-allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[1066] rac-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one;
[1067] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[1068] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol;
[1069] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one;
[1070] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[1071] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol;
[1072] rac-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol;
[1073] (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1074] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[1075] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one;
[1076] (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1077] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-methoxy-1-methylpyrrolidin-2-one;
[1078] (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidin-2-one;
[1079] (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[1080] (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1081] (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1082] (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol;
[1083] (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[1084] (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1085] (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1086] (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one;
[1087] (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol;
[1088] (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one;
[1089] (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1090] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1091] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one;
[1092] (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1093] ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1094] (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido[5,4-c]azepine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1095] (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1096] (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1097] (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1098] (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[1099] (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-ylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1100] (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[1101] (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1102] (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1103] (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1104] (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1105] (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1106] (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1107] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1108] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetamide;
[1109] (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1110] (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino)acetonitrile;
[1111] (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1112] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidine-3-carbonitrile;
[1113] (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1114] (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1115] (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl)azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1116] (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methylazetidine-3-carboxamide;
[1117] (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1118] (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1119] (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1120] (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1121] (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile;
[1122] (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1123] (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1124] (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1125] (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1126] (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1127] (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1128] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl)acetamide;
[1129] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)acetamide;
[1130] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1131] (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1132] (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1133] (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1134] (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1135] (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1136] (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1137] (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1138] (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1139] (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d)methanesulfonamide;
[1140] (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1141] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1142] (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one;
[1143] (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[1144] (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[1145] (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[1146] (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[1147] (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1148] (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1149] (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile;
[1150] (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyridin-2-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1151] (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[3.1.0]hexan-3-one;
[1152] (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1153] (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1154] (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1155] (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1156] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1157] (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1158] (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1159] (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1160] (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1161] (3R,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[1162] (3R,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[1163] (3S,4S*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[1164] (3S,4R*)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidin-2-one;
[1165] (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1166] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1167] (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1168] (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1169] (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1170] (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1171] (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidin-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1172] (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1173] (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1174] (R)-3-[2-[3-[4-amino-8-(cyclopropyloxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1175] (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazol-4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1176] (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1177] (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro[2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1178] (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1179] (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1180] (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1181] (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1182] (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1183] (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1184] (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1185] (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin-1-yl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1186] (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one; and
[1187] or a pharmaceutically acceptable salt thereof.
[1188] An exemplary embodiment of the compound of formula (I) is compound
[1189] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1190] (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1191] (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1192] (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1193] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1194] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1195] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1196] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1197] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1198] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1199] (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1200] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1201] (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1202] (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1203] (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1204] (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1205] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[1206] (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol;
[1207] (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1208] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1209] (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1210] (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridin-5-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1211] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1212] (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1213] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1214] (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1215] (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1216] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1217] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1218] or a pharmaceutically acceptable salt thereof.
[1219] Another exemplary embodiment of the compound of formula (I) is the compound
[1220] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1221] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[1222] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1223] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1224] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1225] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1226] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1227] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1228] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1229] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one;
[1230] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1231] or a pharmaceutically acceptable salt thereof.
[1232] Another exemplary embodiment of the compound of formula (I) is the compound
[1233] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1234] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1235] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1236] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1237] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1238] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one; and
[1239] or a pharmaceutically acceptable salt thereof.
[1240] Another exemplary embodiment of the compound of formula (I) is the compound
[1241] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1242] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1243] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1244] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1245] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1246] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1247] or a pharmaceutically acceptable salt thereof.
[1248] Another exemplary embodiment of the compound of formula (I) is the compound
[1249] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1250] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol;
[1251] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1252] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1253] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1254] or a pharmaceutically acceptable salt thereof.
[1255] Another exemplary embodiment of the compound of formula (I) is the compound
[1256] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one; and
[1257] or a pharmaceutically acceptable salt thereof.
[1258] Another exemplary embodiment of the compound of formula (I) is the compound
[1259] (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol; and
[1260] or a pharmaceutically acceptable salt thereof.
[1261] Another exemplary embodiment of the compound of formula (I) is the compound
[1262] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1263] or a pharmaceutically acceptable salt thereof.
[1264] Another exemplary embodiment of the compound of formula (I) is the compound
[1265] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1266] or a pharmaceutically acceptable salt thereof.
[1267] Another exemplary embodiment of the compound of formula (I) is the compound
[1268] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1269] or a pharmaceutically acceptable salt thereof.
[1270] Another exemplary embodiment of the compound of formula (I) is the compound
[1271] (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1272] or a pharmaceutically acceptable salt thereof.
[1273] Another exemplary embodiment of the compound of formula (I) is the compound
[1274] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1275] or a pharmaceutically acceptable salt thereof.
[1276] Another exemplary embodiment of the compound of formula (I) is the compound
[1277] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1278] or a pharmaceutically acceptable salt thereof.
[1279] Another exemplary embodiment of the compound of formula (I) is the compound
[1280] (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1281] or a pharmaceutically acceptable salt thereof.
[1282] Another exemplary embodiment of the compound of formula (I) is the compound
[1283] (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one; and
[1284] or a pharmaceutically acceptable salt thereof.
[1285] Another exemplary embodiment of the compound of formula (I) is the compound
[1286] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1287] or a pharmaceutically acceptable salt thereof.
[1288] Another exemplary embodiment of the compound of formula (I) is the compound
[1289] (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidin-2-one;
[1290] (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1291] (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1292] (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1293] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1294] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1295] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1296] (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1297] (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1298] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1299] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1300] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1301] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1302] (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1303] (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1304] (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1305] (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1306] (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1307] (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1308] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1309] or a pharmaceutically acceptable salt thereof.
[1310] Another exemplary embodiment of the compound of formula (I) is the compound
[1311] (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1312] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1313] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1314] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1315] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1316] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1317] (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1318] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1319] or a pharmaceutically acceptable salt thereof.
[1320] Another exemplary embodiment of the compound of formula (I) is the compound
[1321] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one;
[1322] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1323] (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1324] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1325] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one;
[1326] and pharmaceutically acceptable salts thereof.
[1327] Another exemplary embodiment of the compound of formula (I) is the compound
[1328] (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one; and
[1329] or a pharmaceutically acceptable salt thereof.
[1330] Another exemplary embodiment of the compound of formula (I) is the compound
[1331] (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1332] or a pharmaceutically acceptable salt thereof.
[1333] Another exemplary embodiment of the compound of formula (I) is the compound
[1334] (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1335] or a pharmaceutically acceptable salt thereof.
[1336] Another exemplary embodiment of the compound of formula (I) is the compound
[1337] (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1338] or a pharmaceutically acceptable salt thereof.
[1339] Another exemplary embodiment of the compound of formula (I) is the compound
[1340] (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one; and
[1341] or a pharmaceutically acceptable salt thereof.
[1342] Another exemplary embodiment of the invention is a method of treating a subject having or diagnosed as having a disease, disorder or medical condition mediated by NIK activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound set forth above.
[1343] Another exemplary embodiment of the invention is a method of treating a subject having or diagnosed as having a disease, disorder or medical condition mediated by NIK activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound set forth above.
[1344] wherein the disease, disorder or medical condition is at least one of: cancer, an inflammatory disorder, an autoimmune disorder, an immunodermatological disorder, and a metabolic disorder.
[1345] Another exemplary embodiment of the invention is a method of treating a subject having or diagnosed as having a disease, disorder or medical condition mediated by NIK activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound set forth above.
[1346] wherein the disease, disorder or medical condition is at least one of: SLE, RA, GvHD, transplant rejection, Sjögren's syndrome, pemphigus vulgaris, palmoplantar pustulosis, hidradenitis suppurativa, obesity and diabetes.
[1347] Additional embodiments of the present invention are pharmaceutical compositions, each comprising an effective amount of at least one of the compounds given above or a pharmaceutically acceptable salt thereof.
[1348] The compounds of the present invention, including pharmaceutically acceptable salts thereof, alone or in combination (collectively, "active agents"), are useful as NIK inhibitors in the methods of the present invention. Such methods for modulating NIK activity comprise exposing NIK to an effective amount of at least one active agent of the present invention.
[1349] In some embodiments, NIK inhibitors are used to diagnose a subject as having or suffering from a disease, disorder, or medical condition mediated by NIK activity, such as those described herein.Symptoms or disease states are intended to be included within the scope of "disease, disorder, or medical condition."
[1350] Thus, the present invention relates to methods of treating a subject diagnosed with or suffering from a disease, disorder, or medical condition mediated by NIK using the agents described herein. As used herein, the term "treating" is intended to refer to administering an agent or composition of the invention to a subject for the purpose of achieving a therapeutic or preventive benefit by modulating NIK. Treatment includes reversing, ameliorating, alleviating, inhibiting the progression of, reducing the severity of, diminishing, or preventing a disease, disorder, or condition mediated by modulation of NIK activity, or one or more symptoms of such a disease, disorder, or condition. The term "subject" refers to a mammalian patient, such as a human, in need of such treatment. The term "inhibitor" refers to a compound that reduces, prevents, inactivates, desensitizes, or downregulates NIK expression or activity.
[1351] When referring to an inhibitory target, an "effective amount" means an amount sufficient to inhibitorily affect NIK activity.
[1352] In the therapeutic method according to the present invention, an effective amount of at least one activating agent according to the present invention is administered to a subject suffering from or diagnosed with such a disease, disorder or medical condition. "Effective amount" means an amount or dosage sufficient to produce a desired therapeutic or preventive beneficial effect in a patient who needs such treatment for a given disease, disorder or medical condition. For a 70 kg person, an exemplary range of dosage is about 1 mg / day to 1000 mg / day in single or multiple dose units.
[1353] Once the patient's disease, disorder, or condition improves, the dosage can be adjusted to a preventative or maintenance treatment. For example, the dosage or frequency of administration, or both, can be reduced to a level that maintains the desired therapeutic or preventative effect, depending on the symptoms. Of course, treatment can be discontinued if symptoms have been alleviated to an appropriate level. However, patients may require long-term intermittent treatment due to any recurrence of symptoms.
[1354] The pharmaceutical compositions of the present invention comprise an effective amount of at least one active agent according to the present invention.
[1355] Pharmaceutically acceptable excipients commonly used in pharmaceutical compositions are substances that are non-toxic, biologically tolerable, and in other words biologically suitable for administration to a subject, such as inert substances, which are added to the pharmaceutical composition or otherwise used as vehicles, carriers, or diluents to facilitate administration of the agent and to be compatible therewith. Examples of such excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
[1356] The delivery form of the pharmaceutical composition containing one or more dosage units of the active agent can be prepared using pharmaceutically acceptable excipients and compounding techniques known or available to those skilled in the art. The composition can be administered in the method of the present invention by a suitable delivery route, for example, by oral, parenteral, rectal, topical or ocular routes, or by inhalation.
[1357] The preparation can be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations or suppositories. The composition can be formulated for any of a variety of administration routes, such as intravenous infusion, subcutaneous injection, topical administration or oral administration.
[1358] For oral administration, the active agent of the present invention can be provided in the form of tablets, capsules, or beads, or as a solution, emulsion or suspension. To prepare an oral composition, the active agent can be formulated to produce, for example, a dosage of about 1 mg / day to 1000 mg / day in a single dose unit or multiple dose units for a 70 kg human as an exemplary range.
[1359] Oral tablets can include one or more active ingredients mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrants, binders, lubricants, sweeteners, flavorings, colorants and preservatives. Suitable inert fillers include sodium carbonate and calcium carbonate, sodium phosphate and calcium phosphate, lactose, starch, sugar, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, etc. Illustrative examples of liquid oral excipients include ethanol, glycerol, water, etc. Disintegrants are exemplified by starch, polyvinylpyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose and alginic acid. Binders can include starch and gelatin. Lubricants (when present) can be magnesium stearate, stearic acid or talc. If desired, tablets can be coated with materials such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or can be coated with an enteric coating. Available additional coatings include coatings designed to release compounds or active agents based on time, pH or bacterial content.
[1360] Capsules for oral administration include hard gelatin capsules and soft gelatin capsules or (hydroxypropyl) methylcellulose capsules. For the preparation of hard gelatin capsules, one or more active ingredients can be mixed with a solid, semisolid or liquid diluent. Soft gelatin capsules can be prepared by mixing the active ingredient with oils such as peanut oil or olive oil, liquid paraffin, a mixture of monoglycerides and diglycerides of short-chain fatty acids, polyethylene glycol 400 or propylene glycol. Orally administered liquids can be in the form of suspensions, solutions, emulsions or syrups, or can be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicles before use. Such liquid compositions may optionally contain: pharmaceutically acceptable excipients, such as suspending agents (e.g., sorbitol, methylcellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, etc.); non-aqueous vehicles, such as oils (e.g., almond oil or fractionated coconut oil), propylene glycol, ethanol or water; preservatives (e.g., methylparaben or propylparaben or sorbic acid); wetting agents, such as lecithin; and, if desired, flavoring or coloring agents.
[1361] The activating agent of the present invention can also be administered by non-oral route. For example, the composition can be formulated into a suppository, enema or foam for rectal administration. For parenteral use, including intravenous, intramuscular, intraperitoneal or subcutaneous routes, the activating agent of the present invention can be provided in a sterile aqueous solution or suspension buffered to an appropriate pH and isotonicity, or provided in an oil acceptable to parenteral administration. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms can be presented in unit dosage form (such as ampoules or disposable injection devices), presented in a multiple dose form (such as a bottle) from which an appropriate dose can be extracted, or presented in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Exemplary infusion doses range from about 1 to 1000 μg / kg / minute of the activating agent mixed with a pharmaceutically acceptable carrier, over a period of several minutes to several days.
[1362] For topical administration, the agent can be mixed with a pharmaceutical carrier. In another mode of administration, the agent of the present invention can be delivered transdermally using a patch formulation.
[1363] Alternatively, the active agent in the method of the present invention may be administered via the intranasal or oral route by inhalation, for example, in the form of a spray formulation also containing a suitable carrier.
[1364] Embodiments of the present invention provide NIK inhibitors contemplated for use in preventing and / or controlling excessive inflammatory responses.
[1365] Exemplary compounds useful in the methods of the present invention are described below with reference to exemplary synthetic schemes ("Schemes") and specific examples of their preparation.
[1366]
[1367] By way of illustration and not limitation, the following general preparation procedures provided according to schemes 1-2 prepare compounds of formula (I). Those of ordinary skill in the art will recognize that, to obtain the various compounds herein, raw materials can be appropriately selected so that, when protected or unprotected as needed, the final desired substituent will be carried throughout the reaction scheme to obtain the desired product. Alternatively, the appropriate group replacing the final desired substituent can be subjected to the entire reaction scheme and, where appropriate, replaced with the desired substituent. Unless otherwise indicated, the variables in schemes 1-2 are all as defined above for formula (I).
[1368] Solution 1
[1369]
[1370] As shown in Scheme 1, the cross-coupling reaction of compound II and compound III provides a compound of formula (I). Compound II is added to compound III using a suitable palladium catalyst such as Pd(PPh3)2Cl2 or (PdCl2[P(cy)3]2), a base such as diisopropylethylamine, TEA or a mixture thereof, a copper catalyst such as CuI, in a solvent such as THF, 1,4-dioxane, acetonitrile, DMF or a mixture thereof, and heated at a temperature of about 40°C to 100°C using microwave or conventional heating for a period of about 2-4 hours to obtain a compound of formula (I).
[1371] Option 2
[1372]
[1373] Compounds of formula (I) are also prepared by alternative cross-coupling reactions using compounds IV and V. The substituent YY in compound V is chloro, bromo, iodo or -SCH3. In these reactions, a suitable palladium catalyst is used, such as bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), XPhos-Pd-G2 precatalyst (chloro(2-dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (PdCl2(dppf)), PdP(Ph3)4, PdCl2(dtbpf)2 or [(di(1-adamantyl)-n-butylphosphine)-2 -(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II), [(bis(1-adamantyl)-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II), a base such as Cs2CO3, K3PO4, NaHCO3, Na2CO3, K2CO3 or a mixture thereof, in a solvent such as H2O, 1,4-dioxane, ethanol, toluene, 1,2-dimethoxyethane or a mixture thereof, compound IV and V are mixed and heated at a temperature in the range of about 40°C to 100°C using microwave or conventional heating for a period of about 2-16 hours.
[1374] In the case where there is a blocking group on the compound of formula (IV) or (V), a final deprotection step is added using conditions known to those skilled in the art to obtain a compound of formula (I). If dimethoxybenzyl is used to protect the anilino group, it can be removed using reagents such as DDQ or ceric ammonium nitrate in a solvent such as DCM, water or a mixture thereof. If the blocking group is benzenesulfonamide, a base such as LiOH, NaOH, KOH can be used in a suitable solvent such as THF, 1,4-dioxane in combination with water and / or MeOH.
[1375] The following specific examples are provided to further illustrate embodiments within the scope of the present invention.
[1376] In obtaining the compounds and corresponding analytical data described in the Examples below, the following experimental and analytical protocols were followed unless otherwise indicated.
[1377] Unless otherwise specified, the reaction solutions were kept at room temperature under N 2(g) or Ar (g) When a solution is "concentrated to dryness", it means that the solution is concentrated under reduced pressure using a rotary evaporator, and when a solution is dried, it means that the solution is usually dried using a drying agent such as MgSO4 or Na2SO4. Unless otherwise stated, a pre-packed silica gel column such as Normal phase silica gel flash column chromatography (FCC) was performed using ethyl acetate (EtOAc) / hexane, CH2Cl2 / MeOH, or CH2Cl2 / 10% 2N NH3 in MeOH as the eluent.
[1378] Thin layer chromatography is performed using silica gel plates, such as Merck silica gel 60F 254 2.5 cm × 7.5 cm, 250 μm or 5.0 cm × 10.0 cm, 250 μm pre-coated silica gel plates. Preparative thin layer chromatography uses silica gel plates such as EM Science silica gel 60F 254 The microwave reaction was carried out at the specified temperature in a microwave reactor such as a CEM Biotage Initiator TM or Optimizer TM Microwave. Unless otherwise indicated, mass spectra were obtained on a mass spectrometer such as an Agilent 1100 series MSD using electrospray ionization (ESI) in positive ion mode. Calculated masses correspond to exact masses. NMR spectra were obtained on an NMR spectrometer such as Bruker model DPX400 (400 MHz), DPX500 (500 MHz), DRX600 (600 MHz). 1 The format of HNMR data is as follows: chemical shift (in ppm) downfield from a tetramethylsilane reference (multiplicity, coupling constant J (in Hz), integration).
[1379] When trifluoroacetic acid salts were obtained, they were obtained by purification of the reaction product by preparative reverse phase HPLC, whereby the final product was isolated as a mono-, di- or tri-trifluoroacetic acid salt.
[1380] The trifluoroacetate or hydrochloride of formula (I) compound are converted into their corresponding free alkali by distributing any such salt between saturated sodium bicarbonate aqueous phase and suitable organic solvent (such as ethyl acetate or dichloromethane).After distribution, separate organic layer, water layer is extracted twice with suitable organic solvent.In order to finally obtain free alkali, the organic extract merged is washed with salt water and is concentrated into dryness.Some examples provided below refer to the free alkali when the corresponding description of the preparation of corresponding salt such as trifluoroacetate or hydrochloride ends.Should be appreciated that the free alkali in this type of example obtains in a manner known to those of ordinary skill in the art, for example, by following above-mentioned distribution and drying process.
[1381] When the yield is given in the form of a percentage, such yield refers to the ratio of the mass of the entity for which the yield is given to the maximum amount of the same entity obtainable under specific stoichiometric conditions. Unless otherwise indicated, the concentration of the reagent given in the form of a percentage refers to the mass ratio. Whether or not explicitly stated, the yields given in the following examples are calculated relative to the dry form of the compound for which any such yield is given.
[1382] Chemical names were generated using ChemDraw Ultra 17.1 (CambridgeSoft Corp., Cambridge, MA) or OEMetaChem V1.4.0.4 (Open Eye).
[1383] Abbreviations and acronyms used herein include the following:
[1384] Table 1. Defined abbreviations and acronyms
[1385]
[1386]
[1387]
[1388] Intermediate 1: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8-amine.
[1389]
[1390] Step A: 3-amino-2-chloroisonicotinic acid. A 5 L round-bottom flask equipped with an overhead stirrer was charged with methyl 3-amino-2-chloroisonicotinate (240 g, 1.29 mmol), MeOH (1.44 L), and water (0.48 L). To the resulting solution was added an aqueous solution (1.20 L) of NaOH (139 g, 3.47 mmol), and the mixture was stirred at 25-30° C. After 2 h, the mixture was diluted with water (0.72 L) and neutralized with concentrated HCl (290 mL, 12 M). The resulting mixture was stirred for 30 minutes. The solid was isolated by filtration, washed with water (240 mL×2), and dried under vacuum at 50-55° C. to give 3-amino-2-chloroisonicotinic acid (224 g, 100%) as an off-white solid. MS (ESI): mass calculated for C7H7ClN2O2: 186.0; m / z found: 187.0 [M+H] + . 1HNMR (400MHz, DMSO-d6) δ13.66 (br s, 1H), 7.62 (d, J = 4.0Hz, 1H), 7.59 (d, J = 4.0Hz, 1H), 6.84 (br s, 2H).
[1391] Step B: 3-Amino-2-chloroisonicotinamide. A 3-L round-bottom flask equipped with an overhead stirrer was charged with 3-amino-2-chloroisonicotinic acid (210 g, 1.22 mol), acetonitrile (2.10 L), and carbonyldiimidazole (236 g, 1.46 mol). The resulting mixture was stirred at 20°C-30°C for 1 hour and then poured into a cooled 20 wt% aqueous ammonia solution (2.56 L). The resulting mixture was stirred for 30 minutes, and the solid was isolated by filtration, washed with water (0.42 L x 2), and dried under vacuum at 50°C-55°C to afford 3-amino-2-chloroisonicotinamide (142 g, 68.1%) as a white solid. MS (ESI): mass calculated for C6H6ClN3O was 171.0; m / z found was 172.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 8.18 (br s, 1H), 7.67 (br s, 1H), 7.61 (d, J = 4.0Hz, 1H), 7.50 (d, J = 4.0Hz, 1H), 6.76 (br s, 2H).
[1392] Step C: 4-(Aminomethyl)-2-chloropyridin-3-amine hydrochloride. A 2 L round-bottom flask equipped with an overhead stirrer was charged with 3-amino-2-chloroisonicotinamide (24.3 g, 142 mmol) and THF (100 mL). The flask was purged with nitrogen and heated to 40-45° C. A solution of BH in THF (1.00 L, 1 M) was added dropwise over 1 h while maintaining the internal temperature at 40-45° C. The resulting mixture was stirred continuously for 1 h and then quenched with MeOH (95.3 g, 2.98 mol). The reaction was then cooled and a 30 wt % HCl solution in EtOH (31.3 g, 284 mmol) was added, followed by stirring for 1 hour. The suspension was filtered and the resulting solid was washed with THF (48 mL x 2), then dried in vacuo at 50-55°C to give 4-(aminomethyl)-2-chloropyridin-3-amine hydrochloride (26.5 g, 81%) as a yellow solid, which was used directly in the next synthetic step.
[1393] Step D: 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine. A 250 mL round-bottom flask was charged with 3-iodobenzaldehyde (18.1 g, 115 mmol), PhI(OAc)2 (62.9 g, 195 mmol), DCM (150 mL) and 4-(aminomethyl)-2-chloropyridin-3-amine hydrochloride (15.0 g, 65 mmol) at 25 °C. After 2 h, the resulting mixture was concentrated to dryness and the residue was purified by FCC to give 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine (9.0 g, 38%). MS (ESI): C 13 The calculated mass of H7ClIN3 is 366.9; the found m / z is 367.9 [M+H] + .
[1394] Step E: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8-amine. A 2 L high pressure reactor was charged with 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine (43.0 g, 0.12 mol) and NH3 solution (645 mL, 2M IPA solution). The reactor was sealed and heated to 125-130°C for 16 h. The resulting mixture was cooled, concentrated to 100 mL, diluted with water (430 mL), and stirred at 20-25°C for 2 h. The product was isolated by filtration and dried to give 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8-amine (35 g, 84%) as a light solid. MS (ESI): C 13 The calculated mass of H9IN4 is 348.0; the observed m / z is 349.0 [M+H] + .
[1395] Intermediate 2: (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one.
[1396]
[1397] Step A: tert-Butyl 3-(methylamino)propionate. A 2 L round-bottom flask equipped with an overhead stirrer was charged with methylamine (500 mL, 3.48 mol, 30 wt% solution in EtOH) and EtOH (500 mL), followed by the dropwise addition of tert-butyl acrylate (100 g, 0.78 mol) at 20-25° C. over 3 h. The resulting mixture was stirred at RT for 3 h and then concentrated to dryness to afford tert-butyl 3-(methylamino)propionate (124 g) as a colorless oil. MS (ESI): CH 17 The calculated mass of NO2 is 159.1; the measured m / z is 160.2 [M+H] + . 1H NMR (400MHz, CDCl3) δ2.79 (t, J = 6.5 Hz, 2H), 2.43 (s, 3H), 2.41 (t, J = 6.5 Hz, 2H), 1.44 (s, 9H).
[1398] Step B: tert-Butyl 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate. A 50 L glass-lined reactor equipped with an overhead stirrer was charged with tert-butyl 3-(methylamino)propionate (900 g, 5.65 mol), diethyl oxalate (827 g, 5.65 mol), and THF (18 L). The resulting mixture was warmed to 50-55 ° C, followed by the addition of t-BuOK (633 g, 5.65 mol) in portions. After stirring for 1 h, the mixture was cooled to 20 ° C, concentrated to dryness, and water (5.00 L) was added to form a suspension. The pH was adjusted to 1-2 with aqueous HCl, and the resulting mixture was stirred at 20-25°C for 1 h, then filtered and dried to give tert-butyl 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate (940 g, 78%) as an off-white solid. 1 H NMR (300MHz, CDCl3) δ8.99(s,1H),3.94(s,2H),3.10(s,3H),1.56(s,9H).
[1399] Step C: 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid. Into a 5L round-bottom flask equipped with an overhead stirrer, 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid tert-butyl ester (500g, 2.34mol) and TFA (2.00L) were charged. The resulting mixture was stirred at 20°C-25°C for 3h and then concentrated to dryness. Acetonitrile (1.50L) was added to the residue and stirred at 20°C-25°C for 1h. The product was separated by filtration and dried to give 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid (357g, 97%) as an off-white solid. 1 H NMR (300MHz, CD3OD) δ4.04–3.98 (m, 2H), 3.08 (s, 3H).
[1400] Step D: 1-Methylpyrrolidine-2,3-dione. A 20 L round-bottom flask equipped with an overhead stirrer was charged with 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid (1000 g, 6.360 mol) and THF (15 L). The resulting mixture was heated to 65°C. After 4 h, the mixture was concentrated to dryness to afford 1-methylpyrrolidine-2,3-dione (712 g, 99%) as a yellow solid.1 HNMR (400MHz, CDCl3) δ3.70 (t, J = 5.7Hz, 2H), 3.13 (s, 3H), 2.72 (t, J = 5.7Hz, 2H).
[1401] Step E: (rac)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one. Ethynylmagnesium bromide (3.50 L, 0.5 M THF solution) was charged into a 10 L round-bottom flask equipped with an overhead stirrer. The flask was purged with nitrogen and cooled to -10 ° C, and then 1-methylpyrrolidine-2,3-dione (120 g, 1.06 mol) was added over a 20 min period. The resulting mixture was warmed to 20 ° C -25 ° C and stirred for 16 h. The resulting mixture was quenched with NH4Cl aqueous solution (120 g dissolved in 360 mL H2O) and subsequently diluted with DCM (3.50 L). After slurrying for 1 h, the suspension was filtered, and the filtrate was dried over anhydrous Na2SO4 (500 g) and treated with activated carbon (24 g). The activated carbon was removed by filtration, and the filtrate was concentrated in vacuo to dryness. The residue was slurried in MTBE (360 mL) at 20-25°C for 1 h. The product was isolated by filtration and then dried to afford (rac)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (81 g, 55%) as a yellow solid. MS (ESI): mass calculated for C7H9NO2: 139.1; m / z found: 140.1 [M+H] + . 1 H NMR (300MHz, CD3OD) δ3.40 (dd, J = 7.7, 5.3Hz, 2H), 3.03 (s, 1H), 2.88 (s, 3H), 2.52–2.41 (m, 1H), 2.21 (dt, J = 12.7, 7.7Hz, 1H).
[1402] Step F: (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one and (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one. The enantiomers of (rac)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one were separated by chiral preparative SFC (CHIRALPAK AS-H 5 μm, 5×25 cm, mobile phase (80% CO 2 , 20% IPA (0.1% DEA)). Detection, UV λ=220-254 nM) to give (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (40%) and (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (Intermediate 3, 40%). Data for (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one: MS (ESI): mass calculated for C 7 H 9 NO 2 139.1; m / z found 140.1 [M+H]+ . 1 H NMR (300MHz, CD3OD) δ3.40 (dd, J = 7.7, 5.3Hz, 2H), 3.03 (s, 1H), 2.88 (s, 3H), 2.52–2.41 (m, 1H), 2.21 (dt, J = 12.7, 7.7Hz, 1H). [α] 20 D =-100.1 (c=1.01, MeOH).
[1403] Intermediate 3: (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one.
[1404]
[1405] Chiral separation of intermediate 2 as described in Step F afforded (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (40%). MS (ESI): mass calculated for C7H9NO2: 139.1; m / z found: 140.1 [M+H] + . 1 H NMR (300MHz, CD3OD) δ3.40 (dd, J = 7.7, 5.3Hz, 2H), 3.03 (s, 1H), 2.88 (s, 3H), 2.52–2.41 (m, 1H), 2.21 (dt, J = 12.7, 7.7Hz, 1H). [α] 20 D =+90.5 (c=1.19, MeOH).
[1406] Intermediate 4: (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)phenyl)ethynyl)pyrrolidin-2-one .
[1407]
[1408] 2-(3-bromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (9.22g, 32.6mmol), (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (5.00g, 35.9mmol) and diethylamine (33.7mL, 326mmol) are suspended in degassed DMF (217mL). Nitrogen is then bubbled through the reactants for 5min. Copper (I) iodide (1.24g, 6.52mmol), bis(triphenylphosphine) palladium (II) chloride (2.29g, 3.26mmol) and triphenylphosphine (1.71g, 6.52mmol) are added to the mixture. The reactants are sealed and then heated to 100°C for 30min. The resulting mixture is then passed through diatomaceous earth such as The plug was washed with DMF and concentrated under reduced pressure. The resulting residue was purified by FCC (0% hexanes over 3 min, 25%-100% EtOAc / hexanes over 25 min, 100% EtOAc over 3 min) to give (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidin-2-one (7.50 g, 67.5%) as an off-white solid. MS (ESI): C 19 H 24 The calculated mass of BNO4 is 341.18; the measured m / z is 342.1 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ7.70–7.68(m,1H),7.66(dt,J=7.4,1.3Hz,1H),7.54(dt,J=7.8,1.5Hz,1H),7.41(td,J= 7.6,0.7Hz,1H),6.44(s,1H),3.37–3.32(m,2H),2.80(s,3H),2.46–2.37(m,1H),2.20–2.02(m,1H),1.30(s,12H).
[1409] Intermediate 5: (S)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)phenyl)ethynyl)pyrrolidin-2-one .
[1410]
[1411] The title compound was prepared using similar conditions described in Intermediate 4 using 2-(3-bromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give (S)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidin-2-one (880 mg, 85%) as a solid. MS (ESI): C 19 H 24 The calculated mass of BNO4 is 341.18; the measured m / z is 342.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.70–7.68(m,1H),7.66(dt,J=7.4,1.3Hz,1H),7.54(dt,J=7.8,1.5Hz,1H),7.41(td,J=7 .6,0.7Hz,1H),6.44(s,1H),3.37–3.32(m,2H),2.80(s,3H),2.46–2.37(m,1H),2.20–2.02(m,1H),1.30(s,12H).
[1412] Intermediate 6: (R)-3-hydroxy-1-methyl-3-((4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxetane (pentaboran-2-yl)phenyl)ethynyl)pyrrolidin-2-one .
[1413]
[1414] A denitrogenated solution of DMF (150 mL) was added to 2-(5-bromo-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6.67 g, 22.4 mmol), (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (3.45 g, 24.8 mmol) and diethylamine (23.2 mL, 224 mmol) in a round-bottom flask. Nitrogen was then bubbled through the mixture for 5 min, followed by the addition of copper (I) iodide (0.86 g, 4.49 mmol), bis(triphenylphosphine) palladium (II) chloride (1.58 g, 2.25 mmol) and triphenylphosphine (1.18 g, 4.49 mmol). The reaction vessel was sealed and heated to 100 ° C for 30 min. The mixture was cooled to RT and filtered through diatomaceous earth such as HPLC. The plug was washed with DMF and concentrated to dryness. The resulting residue was purified by FCC (0% hexanes over 3 min, 25%-100% ethyl acetate / hexanes over 25 min, 100% ethyl acetate over 3 min) to give (R)-3-hydroxy-1-methyl-3-((4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidin-2-one (5.86 g, 73.5%) as an off-white solid. MS (ESI): C 20 H 26 The calculated mass of BNO4 is 355.2; the measured m / z is 356.1 [M+H] + . 1H NMR (500MHz, CDCl3) δ7.84(d,J=1.9Hz,1H),7.37(dd,J=7.9,2.0Hz,1H),7.08(d,J=7.9Hz,1H),3.51-3.47(m,1 H),3.38-3.34(m,1H),2.94(d,J=1.8Hz,3H),2.65-2.61(m,1H),2.51(s,3H),2.38-2.35(m,1H),1.33(s,12H).
[1415] Intermediate 7: 6-chloro-2-methylpyrido[3,2-d]pyrimidin-4-amine .
[1416]
[1417] A vial containing 3-amino-6-chloropyridine carbonitrile (100 mg, 0.65 mmol) was charged with acetamidine hydrochloride (57.0 mg, 0.98 mmol), potassium phosphate (553 mg, 2.6 mmol) and THF (3 mL). The vial was sealed and heated to 80 ° C for 16 h. The resulting mixture was cooled to RT and concentrated to dryness. Water (3 mL) was added to the residue at 70 ° C. After stirring for 30 min, the resulting mixture was cooled to RT and stirred for another 30 min. The resulting solid was separated by filtration and washed with water (3 mL) and Et2O (10 mL) to give 6-chloro-2-methylpyrido[3,2-d]pyrimidin-4-amine (70 mg, 55%) as a light yellow solid. MS (ESI): mass calculated for C8H7ClN4 is 194.04; m / z found is 195.04 [M+H] + . 1 H NMR (400MHz, CDCl3) δ 8.00 (d, J = 8.7 Hz, 1H), 7.62 (d, J = 8.7 Hz, 1H), 6.76 (s, 2H), 2.63 (s, 3H).
[1418] Intermediate 8: 6-chloropyrido[3,2-d]pyrimidin-2-d-4-amine .
[1419]
[1420] A 1 L round-bottom flask was charged with a stirring bar, 3-amino-6-chloropyridinonitrile (22.0 g, 0.14 mol), formamide-d3 (20.6 g, 0.43 mol), K3PO4 (122 g, 0.57 mol) and cyclopentyl methyl ether (440 mL). The resulting mixture was stirred at 65 ° C for 16 h and then cooled to RT. The reaction mixture was then filtered and the filter cake was slurried in water (100 mL) at 20 ° C for 3 h. The solid was isolated by filtration and dried to give 6-chloropyrido [3, 2-d] pyrimidin-2-d-4-amine (23.9 g, 94%) as a yellow solid. MS (ESI): mass calculated for C7H4DClN4 is 181.0; m / z found is 182.0 [M + H] + . 1 H NMR (400MHz, DMSO-d6) δ8.15 (d, J = 8.8 Hz, 1H), 8.05 (br s, 1H), 7.95 (br s, 1H), 7.88 (d, J = 8.8 Hz, 1H).
[1421] Intermediate 9: 2-(5-iodo-2-methylphenyl)thiazolo[5,4-d]pyrimidin-7-amine.
[1422]
[1423] Step A: N-(4-amino-6-oxo-1,6-dihydropyrimidin-5-yl)-5-iodo-2-methylbenzamide. A 2 L round-bottom flask equipped with an overhead stirrer was charged sequentially with 5,6-diaminopyrimidin-4(3H)-one (47.3 g, 375 mmol), 5-iodo-2-methylbenzoic acid (108 g, 412 mmol), DMF (710 mL), and DIEA (153 g, 1.18 mol). The flask was purged with nitrogen and cooled to 0-10°C before adding 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (148 g, 390 mmol). The resulting mixture was stirred at 0-10°C for 1 hour, then heated to room temperature and stirred for 18 hours. The mixture was diluted with acetonitrile (709 mL) and stirred for 30 min. The resulting solid was filtered and washed with acetonitrile (190 mL × 3). The filter cake was collected and dried under vacuum at 50 ° C -55 ° C to give N- (4-amino-6-oxo-1,6-dihydropyrimidin-5-yl) -5-iodo-2-methylbenzamide (108 g, 78.0%) as a light brown solid. 1H NMR (400MHz, DMSO-d6) δ11.68(s,1H),8.89(s,1H),8.01(s,1H),7.78(s,1H),7.66(d,J=8.0Hz,1H),7.05(d,J=8.0Hz,1H),6.39(s,2H),2.35(s,3H).
[1424] Step B: 2-(5-iodo-2-methylphenyl)thiazolo[5,4-d]pyrimidin-7-amine. A 2 L round-bottom flask equipped with an overhead stirrer was charged with N-(4-amino-6-oxo-1,6-dihydropyrimidin-5-yl)-5-iodo-2-methylbenzamide (110 g, 297 mmol), pyridine (1.10 L) and P2S5 (165 g, 742 mmol). The resulting mixture was heated at 100 ° C for 1 h and then cooled to RT. The mixture was concentrated to dryness, diluted with acetonitrile (550 mL), and neutralized with 1N HCl (1.20 L). The resulting mixture was stirred for 1 h, and the suspension was filtered, washed with MeOH (110 mL×3), and dried under vacuum at 50° C.-55° C. The resulting solid was further purified by adding MeOH (1150 mL) at 60 ° C and stirring for 1 h. The solid was collected by filtration and dried in vacuo at 50-55°C to give 2-(5-iodo-2-methylphenyl)thiazolo[5,4-d]pyrimidin-7-amine (88.4 g, 80.8%) as a light yellow solid. 1 HNMR (300MHz, DMSO-d6) δ8.33(s,1H),8.15(d,J=1.9Hz,1H),7.81(d,J=2.0Hz,2H),7.78(d,J=1.9Hz,1H),7.23(d,J=8.1Hz,1H),2.57(s,3H).
[1425] Intermediate 10: (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol.
[1426]
[1427] Step A: 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol. A 5 L 3-necked round-bottom flask purged and maintained with nitrogen was charged with 1H-imidazole (200 g, 2.93 mol), prop-2-enal (247 g, 4.41 mol), AcOH (12.3 g, 205 mmol) and dioxane (2.00 L). The resulting solution was stirred at 100 ° C for 4 h. The resulting mixture was cooled to RT and concentrated to dryness. The residue was purified by FCC (DCM / MeOH (30:1)) to give 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (125 g, 34.3%) as a white solid. MS (ESI): mass calculated for C6H8N2O is 124.0; m / z found is 125.0 [M+H] + .
[1428] Step B: 5,6-dihydro-7H-pyrrolo[1,2-a]imidazol-7-one. A 5 L 3-necked round-bottom flask purged and maintained with nitrogen was charged with 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (125 g, 1.00 mol), DCM (2.5 L) and MnO2 (615 g, 7.10 mol). The resulting solution was stirred at 25 ° C. After 72 h, the solid was removed by filtration. The resulting mixture was concentrated and the residue was purified by FCC (DCM / MeOH (30:1)) to give 5,6-dihydro-7H-pyrrolo[1,2-a]imidazol-7-one (67 g, 54.5%) as a yellow solid. MS (ESI): mass calculated for C6H6N2O is 122.0; m / z found is 123.0 [M+H] + .
[1429] Step C: (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol and (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol. To a stirred mixture of 5,6-7H-pyrrolo[1,2-a]imidazol-7-one (67.0 g, 549 mmol) in DCM (1.5 L) was added dropwise bromo(ethynyl)magnesium (213 g, 1.65 mmol) at 0 ° C under a nitrogen atmosphere. The resulting solution was stirred at 25 ° C for 1 h. The reaction was then quenched with saturated aqueous NH4Cl (500 mL). The resulting mixture was concentrated and extracted with ethyl acetate (1 L×2). The combined organic extracts were washed with water (500 mL) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by FCC (DCM:MeOH (20:1)) to give 7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (23.9 g, 29.4%) as a white solid. The enantiomers of racemic-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol were separated by chiral preparative SFC (CHIRALPAK AD-3 3.0×100 mm, 3 μm; mobile phase, EtOH (0.1% DEA); 10% to 50% in 4.0 min, hold at 50% for 2.0 min; 2 mL / min. Column temperature: 35° C. UVλ=220-254 nM) to give (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (6.2 g) as a white solid and (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (Intermediate 11, 5.6 g) as a white solid. Data for (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol: MS (ESI): mass calculated for C8H8N2O: 148.0; m / z found: 149.0 [M+H] + . 1 H NMR (400MHz, CD3OD) δ7.12-7.00(m,2H),4.19-4.02(m,2H),3.14(s,1H),3.06-3.01(m,1H),2.83-2.78(m,1H). [α] 20 D =-60.7 (c=0.29, MeOH).
[1430] Intermediate 11: (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol.
[1431]
[1432] Chiral separation of intermediate 10, Step C, provided (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (5.6 g) as a white solid. MS (ESI): mass calculated for C8H8N2O: 148.0; m / z found: 149.0 [M+H] + . 1 H NMR (400MHz, CD3OD) δ7.12-7.00(m,2H),4.19-4.02(m,2H),3.14(s,1H),3.06-3.01(m,1H),2.83-2.78(m,1H). [α] 20 D =+59.6 (c=0.27, MeOH)
[1433] Intermediate 12: 2-(3-iodophenyl)-1,7-naphthyridin-8-amine.
[1434]
[1435] Steps A: 6-chloro-3-picolinecarboxamide.To the mixture of 6-chloro-3-picolinecarboxylic acid (450g, 2.62mol) in DCM (3.00L), drip (COCl) 2 (466mL, 5.32mol), then at 0 ℃, in 30min, slowly drip DMF (38.3mL, 498mmol).After 2h, gained mixture is warming up to RT and is concentrated into dryness.Resistates is diluted with DCM (500mL) and is added drop-wise to NH 3 -H 25.0%v / v solution of NH 3) at 0 ℃ of.After 3h, filter gained mixture and filtrate is concentrated into dryness, obtain 6-chloro-3-picolinecarboxamide (390g, 78.5%) as yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.89 (br s, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.59 ( br s, 1H), 7.53 ( d, J = 8.2 Hz, 1H), 2.45 ( s, 3H).
[1436] Step B: (E)-6-chloro-N-((dimethylamino)methylene)-3-methylpicolinamide. To a mixture of 6-chloro-3-methylpicolinamide (195 g, 1.14 mol) in THF (1.20 L) was added DMF-DMA (699 mL, 5.26 mol) at RT. The resulting mixture was heated to 90° C. After 16 h, the mixture was cooled to RT and concentrated to dryness to afford (E)-6-chloro-N-((dimethylamino)methylene)-3-methylpicolinamide (540 g) as a dark brown oil, which was used directly in the next step.
[1437] Step C: 2-iodo-1,7-naphthyridine-8 (7H) -one. At RT, t-BuOK (798mL, 1.00M THF solution) was added once to a mixture of (E) -6- chloro-N- ((dimethylamino) methylene) -3-methylpicolinamide (180g, 798mmol) in THF (900mL). The brown mixture was heated to 90 ° C. After 3h, the mixture was cooled to RT and concentrated to dryness. Ice (200g) was added to the resulting residue, the pH was adjusted to 4 using 1M HCl, and MeCN (400mL) was added. The resulting mixture was heated at 80 ° C for 4h. The mixture was then slowly cooled to 25 ° C and stirred for another 8h. The resulting solid was collected by filtration and dried in vacuo to give 2- chloro-1,7-naphthyridine-8 (7H) -one (276g, 63.9% yield) as a yellow solid. MS (ESI): mass calculated for C8H5ClN2O: 180.0; m / z found: 181.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.21 (d, J = 8.44Hz, 1H), 7.77 (d, J = 8.44Hz, 1H), 7.32 (d, J = 6.97Hz, 1H), 6.60 (d, J = 6.97Hz, 1H).
[1438] Step D: 2-(3-aminophenyl)-1,7-naphthyridin-8(7H)-one. To a mixture of 2-chloro-1,7-naphthyridin-8(7H)-one (113 g, 626 mmol) in toluene (678 mL), MeOH (339 mL) and H2O (113 mL) was added (3-aminophenyl)boronic acid (103 g, 751 mmol), Na2CO3 (133 g, 1.25 mol), Pd(PPh3)4 (14.5 g, 12.5 mmol) under nitrogen. The resulting mixture was heated to 90 ° C for 12 hours. The resulting mixture was cooled to RT, the organic solvent was concentrated, and the remaining mixture was poured into water (2.5 L). The resulting suspension was filtered and the collected yellow solid was washed with water (500 mL×4). The yellow solid was triturated with EtOAc (1.5 L) and dried to give 2-(3-aminophenyl)-1,7-naphthyridin-8(7H)-one (304 g, 83.8%) as a yellow solid. MS (ESI): C 14 H 11 The calculated mass of N3O is 237.1; the found m / z is 238.2 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ11.51(br s,1H),8.05-8.17(m,2H),7.48(t,J=1.83Hz,1H),7.23-7.32(m,2H),7.16(t,J= 7.76Hz, 1H), 6.67 (dd, J = 1.47, 7.95Hz, 1H), 6.55 (d, J = 7.09Hz, 1H), 5.25 (s, 2H).
[1439] Step E: 2-(3-iodophenyl)-1,7-naphthyridin-8(7H)-one. To a mixture of 2-(3-aminophenyl)-1,7-naphthyridin-8(7H)-one (80.0 g, 337 mmol) and CuI (77.1 g, 405 mmol), CH2I2 (136 mL, 1.69 mol) in THF (800 mL) was added t-BuONO (120 mL, 1.01 mol) at 25°C. The resulting mixture was then heated to 70°C. After 1 h, the mixture was cooled to RT, filtered, and the filtrate was concentrated to dryness to give 2-(3-iodophenyl)-1,7-naphthyridin-8(7H)-one (200 g) as a yellow solid, which was used directly in the next step. MS (ESI): C 14 The calculated mass of H9IN2O is 347.9; the found m / z is 349.0 [M+H] + .
[1440] Step F: 8-chloro-2-(3-iodophenyl)-1,7-naphthyridine. 2-(3-iodophenyl)-1,7-naphthyridine-8(7H)-one (330 g, 948 mmol) was added portionwise to POCl3 (1.98 L, 21.3 mol) in a 5 L round-bottom flask. The resulting mixture was heated to 120 ° C. After 12 h, POCl3 was removed from the container by distillation at 120 ° C, and the remaining residue was quenched with water (3 L). The mixture was adjusted to pH = 9 with solid NaHCO3, and the resulting mixture was partitioned between ethyl acetate (2 L) and water (1 L). The organic layer was separated, washed with ammonium hydroxide (800 mL×3) and brine (600 mL), dried over Na2SO4, filtered and concentrated to give 8-chloro-2-(3-iodophenyl)-1,7-naphthyridine (80.0 g) as a brown solid, which was used directly in the next step. MS (ESI): C 14 The calculated mass of H8ClIN2 is 365.9; the found m / z is 366.6 [M+H] + .
[1441] Step G: 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1,7-naphthyridine-8-amine. To (4-methoxyphenyl)methanamine (265 mL, 2.05 mol) was added 8-chloro-2-(3-iodophenyl)-1,7-naphthyridine (75.0 g, 205 mmol), and the resulting mixture was heated to 120 ° C for 3 h. The mixture was cooled to RT and the pH was adjusted to pH = 1 using 1M HCl. Ethyl acetate (300 mL) was added and the resulting mixture was filtered. The collected solid was washed with water and dried in vacuo to give 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1,7-naphthyridine-8-amine (61.0 g, 89.0%) as a yellow solid, which was used directly in the next step. MS (ESI): C 22 H 18 The calculated mass of IN3O is 467.1; the found m / z is 468.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ10.27(br s,1H),8.79(s,1H),8.60-8.65(m,1H),8.56-8.47(m,2H),7.92(d,J=7.82Hz,1H),7.71(d,J=6.97 Hz,1H),7.42-7.47(m,2H),7.41-7.34(m,1H),7.27(d,J=6.97Hz,1H),6.95-6.90(m,2H),4.98(br d,J=6.4Hz,2H),3.72(s,3H).
[1442] Step H: 2-(3-iodophenyl)-1,7-naphthyridin-8-amine. A solution of 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1,7-naphthyridin-8-amine (60.0 g, 128 mmol) in TFA (150 mL) was stirred at 60 ° C. After 0.75 h, the mixture was concentrated to dryness. The resulting residue was partitioned between ethyl acetate (500 mL) and saturated aqueous NaHCO3 (200 mL). The organic layer was separated and washed with saturated aqueous NaHCO3 (200 mL x 2) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to dryness. The resulting residue was purified sequentially by FCC (petroleum ether:ethyl acetate = 100:1 to 1:1) and preparative HPLC (Phenomenex Luna C18 10 μm, 250×50 mm; mobile phase: 20% ACN:water (0.1% TFA) increasing in gradient to 50% ACN over 28 min. Detection, UVλ = 220-254 nM) to give 2-(3-iodophenyl)-1,7-naphthyridin-8-amine (24.8 g, 52.1%) as a yellow solid. MS (ESI): C 14 H 10 The calculated mass of IN3 is 346.9; the found m / z is 348.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.48(s,1H),8.06(d,J=8.4Hz,2H),7.99-7.91(m,2H),7.81(d,J=7.8Hz,1H),7.28-7.24(m,1H),6.94(d,J=5.9Hz,1H),6.31(br s,2H).
[1443] Intermediate 13: (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol.
[1444]
[1445] Step A: 1-(5-methyl-1,3,4-oxadiazol-2-yl)ethan-1-one. A 2 L 3-necked round-bottom flask was charged with a solution of N-methoxy-N,5-dimethyl-1,3,4-oxadiazole-2-carboxamide (56.0 g, 327 mmol) in THF (500 mL). The resulting solution was cooled to 0°C and methylmagnesium bromide (320 mL, 2M THF solution) was added dropwise with stirring. After maintaining at 0°C for 1 h, saturated aqueous NH4Cl solution (300 mL) was added. The resulting mixture was extracted with ethyl acetate (200 mL x 3), and the combined organic extracts were washed with brine (200 mL). The organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by FCC (ethyl acetate:petroleum ether (0:1-1:2)) to give 1-(5-methyl-1,3,4-oxadiazol-2-yl)ethan-1-one (21 g, 51%) as a yellow solid. MS (ESI): mass calculated for C5H6N2O2: 126.0; m / z found: 127.0 [M+H] + .
[1446] Step B: (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol and (R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol. A 1 L 3-necked round-bottom flask purged and maintained with nitrogen was charged with bromo(ethynyl)magnesium (500 mL, 2M THF solution). The solution was cooled to 0°C, and a solution of 1-(5-methyl-1,3,4-oxadiazol-2-yl)ethan-1-one (21.0 g, 167 mmol) in THF (200 mL) was added dropwise. The resulting solution was stirred at RT for 2 h. The reaction mixture was cooled to 0°C and saturated aqueous NH4Cl solution (300 mL) was added, followed by H2O (200 mL). The mixture was extracted with ethyl acetate (200 mL×3), and the combined organic extracts were washed with brine (200 mL). The organic extracts were dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by FCC (ethyl acetate / petroleum ether (0:1-1:2)) to give (rac)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (15.2 g, 60%) as a yellow solid. The (R) and (S) enantiomers of (rac)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (15.2 g) were separated by chiral preparative SFC (Phenomenex Lux 5u cellulose-4 5 μm, 5×25 cm; mobile phase, CO2 (80%), IPA (0.1% DEA) (20%). Detector, UV The reaction mixture was separated by elution with a 5% HPLC-MS / MS (220 nm) to afford (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (5.3 g, 35%, >97% ee) as a yellow solid. ((R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (Intermediate 14, 5.2 g, 34%, >97% ee) was also obtained as a yellow solid. Data for (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol: MS (ESI): mass calculated for C7H8N2O2: 152.0; m / z found: 153.0 [M+H] + . 1 HNMR (400MHz, CDCl3) δ2.99(s,1H),2.70(s,1H),2.58(s,3H),1.97(s,3H). [α] 20 D =+23.7 (c=1.06, MeOH).
[1447] Intermediate 14: (R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol.
[1448]
[1449] Chiral separation of Intermediate 13, Step B, provided ((R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (5.2 g, 34%, >97% ee) as a yellow solid. MS (ESI): mass calculated for C7H8N2O2, 152.0; m / z found, 153.0 [M+H] + . 1 HNMR (400MHz, CDCl3) δ2.99(s,1H),2.70(s,1H),2.58(s,3H),1.97(s,3H). [α] 20 D =-20.5 (c=0.96, MeOH).
[1450] Intermediate 15: 7-(3-iodophenyl)-5,6,7,8-tetrahydro-2,7-naphthyridin-1-amine .
[1451]
[1452] 5,6,7,8-tetrahydro-2,7-naphthyridin-1-amine (500 mg, 3.35 mmol) was added to 3-iodophenylboronic acid (1.08 g, 4.36 mmol), Cu(OAc)2 (122 mg, 0.672 mmol), powdered The mixture was stirred at 35°C for 24 h under O2 (15 psi). The mixture was cooled to RT and filtered through celite such as The mixture was filtered through a pad of 4% paraffin (5% ethyl acetate) and washed with DCM (15 mL). The filtrate was concentrated to dryness and the residue was purified by FCC (petroleum ether: ethyl acetate = 1:0 to 0:1) to give 7-(3-iodophenyl)-5,6,7,8-tetrahydro-2,7-naphthyridin-1-amine (260 mg, 21%) as a yellow oil. LCMS (ESI): C 14 H 14 The calculated mass of IN3 is 351.0; the found m / z is 351.8 [M+H] + .
[1453] Intermediate 16: 5-(3-iodophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine.
[1454]
[1455] Step A: 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine. To a solution of 5-chloro-1H-pyrazolo[4,3-b]pyridine (47.8 g, 311 mmol) in H2SO4 (700 mL) at 0°C was added nitric acid (327 g, 3.58 mol, 69.0% purity). The mixture was stirred at 25°C for 2 h, then H2O (100 mL) was added. The resulting mixture was filtered and the collected solid was washed with H2O (20 mL x 3). The resulting solid was triturated with ethyl acetate:DCM = 1:1 at 25°C for 1 h to give 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine (47.0 g, 74.2%) as a white solid. MS (ESI): Mass calculated for C6H3ClN4O2: 197.9; m / z found: 199.0 [M+H]. + .
[1456] Step B: 3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine. To a solution of 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine (9.00 g, 45.3 mmol), trimethyl-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]silane (31.3 g, 90.6 mmol), KCO (21.9 g, 158 mmol), 1,2-dimethoxyethane (160 mL), ethanol (160 mL), and H0 (120 mL) was added Pd(PPh)Cl (3.18 g, 4.53 mmol). The mixture was stirred at 90° C. for 24 h. Ethyl acetate (200 mL) was added to the resulting yellow mixture and the mixture was filtered. The filtrate was washed with H2O (200 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was ground with MTBE at 25 ° C for 30 min, and the resulting solid was collected by filtration to give 3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (12.0 g, 68.3%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.28 (s, 1H), 8.19-8.17 (m, 2H), 7.87 (d, J = 8.8Hz, 1H), 7.59-7.49 (m, 2H), 0.32 (s, 9H).
[1457] Step C: 5-(3-iodophenyl)-3-nitro-1H-pyrazolo[4,3-b]pyridine. To a solution of 3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (17.0 g, 54.4 mmol) in TFA (85.0 mL) was charged N-iodosuccinimide (13.3 g, 59.1 mmol) and chlorotrimethylsilane (690 μL, 5.44 mmol). The resulting mixture was stirred at 25 ° C., and after 1 h, saturated aqueous Na2SO3 solution (20 mL) and ethyl acetate (20 mL) were added to the resulting mixture. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE at 25° C. for 30 min, and the resulting solid was collected by filtration to give 5-(3-iodophenyl)-3-nitro-1H-pyrazolo[4,3-b]pyridine (12.0 g, 55.9%) as a yellow solid. MS (ESI): C 12 The calculated mass of H7IN4O2 is 365.9; the found m / z is 367.0 [M+H] + .
[1458] Step D: 5-(3-iodophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine. To a solution of 5-(3-iodophenyl)-3-nitro-1H-pyrazolo[4,3-b]pyridine (9.50 g, 25.9 mmol) in EtOH (190 mL) was added tin(II) chloride dihydrate (23.4 g, 103 mmol). The mixture was stirred at 80 ° C for 1 h. EtOH (100 mL) was added to the resulting yellow mixture and the mixture was filtered. The organic layer was concentrated to dryness and saturated NaHCO3 solution (100 mL) was added to the residue. The resulting mixture was extracted with ethyl acetate (200 mL×3). The combined organic extracts were dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with DCM (20 mL) at 25° C. for 30 min, and the resulting solid was collected by filtration to give 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine (2.60 g, 29.8%) as a yellow solid. MS (ESI): C 12 The calculated mass of H9IN4 is 335.9; the observed m / z is 337.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.74(s,1H),8.55(s,1H),8.11(d,J=7.8Hz,1H),7.87-7.84(m,1H),7.77(m,2H),7.28(t,J=7.8Hz,1H),5.48(br s,2H).
[1459] Intermediate 17: 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine .
[1460]
[1461] Step A: 5-chloro-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine. To a DMF (4mL) solution of 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine (400mg, 2.01mmol) was added iodomethane (286mg, 2.01mmol) and K2CO3 (278mg, 2.01mmol). The mixture was heated to 50°C. After 3h, the resulting mixture was poured into ice water (20mL), filtered and the solid was collected. The solid was suspended in DCM (10mL) and ethyl acetate (5mL) and stirred at RT for 2h. The solid was separated by filtration and dried under reduced pressure to give 5-chloro-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (268mg, 63%) as a yellow solid. MS (ESI): mass calculated for C7H5ClN4O2: 212.0; m / z found: 213.0 [M+H] + .
[1462] Step B: 1-Methyl-3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine. To a mixture of 5-chloro-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (20.0 g, 94.0 mmol), trimethyl(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)silane (20.0 g, 103 mmol), KCO (26.0 g, 188 mmol) in H2O (70 mL), EtOH (70 mL), and DME (70 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (3.44 g, 4.70 mmol) under nitrogen. The mixture was sparged with nitrogen and then heated to 90°C. After 16 h, the black mixture was filtered and water (500 mL) was added. The aqueous phase was extracted with ethyl acetate / IPA (2.5 L / 0.25 L) and the organic phase was washed with brine (300 mL). The organic extract was dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE (100 mL) at 25 ° C for 16 h, and the resulting solid was collected by filtration to give 1-methyl-3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (3.80 g, 12.4% yield) obtained as a brown solid. MS (ESI): C 16 H 18The calculated mass of N4O2Si is 326.1; the measured m / z is 327.1 [M+H] + .
[1463] Step C: 5-(3-iodophenyl)-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine. To a solution of 1-methyl-3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (4.70 g, 14.4 mmol) in TFA (50 mL) was charged N-iodosuccinimide (3.24 g, 14.4 mmol) and chlorotrimethylsilane (182 μL, 1.44 mmol). The mixture was stirred under nitrogen at 25 ° C for 30 min. The resulting black mixture was concentrated to dryness. The resulting residue was diluted with DCE (10 ml) and concentrated to dryness three times. The product was triturated with MTBE at 25° C. for 1 h, and the resulting solid was collected by filtration to give 5-(3-iodophenyl)-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (4.2 g, 77%) as a black solid. MS (ESI): C 13 The calculated mass of H9IN4O2 is 379.9; the found m / z is 381.1 [M+H] + .
[1464] Step D: 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine. To a solution of 5-(3-iodophenyl)-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (6.30 g, 16.5 mmol) in EtOH (60 mL) was added tin(II) chloride dihydrate (14.9 g, 66.2 mmol). The mixture was stirred at 80°C for 4 h. To the resulting black mixture was added saturated aqueous NaHCO3 (200 mL). The mixture was extracted with ethyl acetate (200 mL x 3). The combined organic extracts were dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by FCC to give 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine, which was triturated with MTBE (30 mL) to give 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine (2.58 g, 45%) as a yellow solid. MS (ESI): C 13 H 11 The calculated mass of IN4 is 350.0; the found m / z is 350.8 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.51-8.61(m,1H),8.13(d,J=8.0Hz,1H),7.93(s,2H),7.74(d,J=7.8Hz,1H),7.28(t,J=7.9Hz,1H),5.58(s,2H),3.79(s,3H).
[1465] Intermediate 18: 6-chloro-4-methylpyrido[3,2-d]pyrimidine .
[1466]
[1467] 4,6-dichloropyrido [3,2-d] pyrimidine (350 mg, 1.75 mmol) and THF (12 mL) were charged into a microwave vial. The mixture was aerated with argon for 5 min and then treated with Pd (PPh 3 ) 4 (202 mg, 0.18 mmol). The resulting mixture was aerated with argon for 5 min and then Al (CH 3 ) 3 (0.42 mL, 2 M THF solution) was added at 0 ° C. The mixture was microwave irradiated for 1 h at 70 ° C. After the reaction mixture was cooled to RT, it was poured into a saturated NH 4 Cl aqueous solution (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic extracts were concentrated to dryness and purified by FCC (petroleum ether: ethyl acetate = 1: 0 to 1: 1) to give 6-chloro-4-methylpyrido [3,2-d] pyrimidine (120 mg, 38%) as a yellow solid. MS (ESI): The calculated mass of C8H6ClN3 is 179.03 。 m / z found: 179.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.25 (s, 1H), 8.48 (d, J = 9.0Hz, 1H), 8.08 (d, J = 8.8Hz, 1H), 2.93 (s, 3H).
[1468] Intermediate 19: 6-chloro-4-ethoxypyrido[3,2-d]pyrimidine .
[1469]
[1470] 4,6-Dichloropyrido[3,2-d]pyrimidine (300 mg, 1.50 mmol) was added to a suspension of NaHCO3 (372 mg, 4.43 mmol) and EtOH (20 mL). The resulting mixture was heated to 85 ° C. under a nitrogen atmosphere for 12 h before cooling to RT. The mixture was concentrated to dryness and H2O (5 mL) was added with stirring at RT. After 2 h, the resulting suspension was separated by filtration and the filter cake was washed with water (1 mL×3), and then dried under reduced pressure to give 6-chloro-4-ethoxypyrido[3,2-d]pyrimidine (300 mg, 92%) as a white solid. MS (ESI): The mass calculated value of C9H8ClN3O is 209.04 。 m / z found: 210.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.89 (s, 1H), 8.39 (d, J = 8.8Hz, 1H), 8.03 (d, J = 8.8Hz, 1H), 4.64 (q, J = 7.0Hz, 2H), 1.47 (t, J = 7.0Hz, 3H).
[1471] Intermediate 20: 6-chloro-N,N-dimethylpyrido[3,2-d]pyrimidin-4-amine .
[1472]
[1473] A 20 mL vial containing 4,6-dichloropyrido[3,2-d]pyrimidine (300 mg, 1.50 mmol) was charged with DMF (8 mL) and DIEA (0.52 mL, 3.02 mmol) at RT. A 40% aqueous solution of N,N-dimethylamine (0.19 mL, 1.5 mmol) was added dropwise to the resulting solution over 2 min. After 45 min, the resulting mixture was concentrated and the residue was purified by FCC (100% DCM increasing to 5% MeOH-DCM) to afford 6-chloro-N,N-dimethylpyrido[3,2-d]pyrimidin-4-amine (145 mg, 46%) as a yellow solid. MS (ESI): mass calculated for C9H9ClN4: 208.65; m / z found: 209.05 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.57 (s, 1H), 8.01 (d, J = 8.8Hz, 1H), 7.55 (d, J = 8.8Hz, 1H), 3.63 (s, 6H).
[1474] Intermediate 21: 4-(azetidin-1-yl)-6-chloropyrido[3,2-d]pyrimidine .
[1475]
[1476] To a mixture of 4,6-dichloropyrido[3,2-d]pyrimidine (250 mg, 1.25 mmol), DIPEA (0.87 mL, 5.00 mmol) and DMF (2.5 mL) was added azetidine (71.3 mg, 1.25 mmol). The resulting mixture was stirred at RT. After 1.5 h, the resulting mixture was filtered and the filter cake was dried under reduced pressure to give 4-(azetidin-1-yl)-6-chloropyrimido[3,2-d]pyrimidine (200 mg, 73%) as a white solid. MS (ESI): C 10 The calculated mass of H9ClN4 is 220.05; the found m / z is 221.05 [M+H] + . 1 H NMR (400MHz, CD3OD) δ8.34 (s, 1H), 7.97 (d, J = 8.8Hz, 1H), 7.69 (d, J = 8.8Hz, 1H), 4.88 (t, J = 7.7Hz, 2H), 4.36 (t, J = 7.7Hz, 2H), 2.82-2.21 (m, 2H).
[1477] Intermediate 22: 6-chloro-N-methylpyrido[3,2-d]pyrimidin-4-amine .
[1478]
[1479] A 20 mL round-bottom flask was charged with 6-chloropyrido[3,2-d]pyrimidin-4-amine (200 mg, 1.11 mmol) and DMF (4 mL), followed by the addition of NaH (36.0 mg (60% purity), 0.90 mmol) in portions at 0°C. To the resulting mixture was added iodomethane (2.20 g, 16.0 mmol) dropwise at 0°C. The resulting mixture was stirred for 5 h while gradually warming to RT, then quenched with aqueous HCl (1 mL, 1 M). The resulting solution was directly purified by preparative HPLC (Xtimate C18×10μm, 250mm×50mm, (eluent: 18% to 48% (v / v) CH3CN and H2O containing 0.04% NH3·H2O and 10mM NH4HCO3). Detection, UVλ=220-254nM) to afford 6-chloro-N-methylpyrido[3,2-d]pyrimidin-4-amine (100mg, 47%) as a white solid. MS (ESI): mass calculated for C8H7ClN4: 194.04; m / z found: 195.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 8.50-8.43 (m, 2H), 8.11 (d, J = 8.8Hz, 1H), 7.83 (d, J = 8.8Hz, 1H), 2.97 (d, J = 4.9Hz, 3H).
[1480] Intermediate 23: 6-(3-bromophenyl)-N-(2,4-dimethoxybenzyl)pyrimido[5,4-d]pyrimidin-4-amine .
[1481]
[1482] Step A: 8-chloro-2-(methylthio)pyrido[5,4-d]pyrimidine. To a 250 mL round-bottom flask containing 6-(methylthio)pyrimido[5,4-d]pyrimidin-4-ol (3.80 g, 19.6 mmol) and toluene (100 mL) was added phosphorus oxychloride (11.0 mL, 120 mmol). The resulting mixture was stirred while heating at 115°C for 15 h, then cooled to RT. The resulting mixture was slowly poured into H2O (100 mL) and the pH of the mixture was adjusted to pH = 7-8 with solid K2CO3. The resulting mixture was extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with saturated aqueous NaHCO3 (35 mL), brine (35 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness. The resulting residue was triturated with MTBE:ethyl acetate (1:1, 50 mL) and the resulting solid was isolated by filtration to provide 8-chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine (2.5 g, 60%) as a grey solid. 1 H NMR (400MHz, DMSO-d6) δ9.11(s,1H),8.14(s,1H),2.56(s,3H).
[1483] Step B: N-(2,4-Dimethoxybenzyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine. A 250 mL round-bottom flask was charged with 8-chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine (3.1 g, 15 mmol), 1-butanol (150 mL), (2,4-dimethoxyphenyl)methanamine (2.7 mg, 16 mmol), and DIPEA (7.3 mL, 44 mmol). The resulting mixture was stirred while heating at 120°C for 2.5 h, then cooled to RT, concentrated to dryness, and diluted with ethyl acetate (250 mL). The organic layer was washed with brine (100 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give N-(2,4-dimethoxybenzyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine (5.16 g) as a brown solid, which was used in the next step without further purification. 1H NMR (400MHz, DMSO-d6) δ9.18(s,1H),8.75(t,J=8.0Hz,1H),8.47(s,1H),7.05(d,J=8.8Hz,1H),6.58(d ,J=2.0Hz,1H),6.43(dd,J=2.4,8.4Hz,1H),4.70-4.64(m,2H),3.84(s,3H),3.72(s,3H),2.68(s,3H).
[1484] Step C: 6-(3-bromophenyl)-N-(2,4-dimethoxybenzyl)pyrimido[5,4-d]pyrimidin-4-amine. A 100 mL three-necked round-bottom flask was charged with N-(2,4-dimethoxybenzyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine (500 mg, 1.46 mmol), (3-bromophenyl)boronic acid (585 mg, 2.91 mmol), and 1,4-dioxane (10 mL). The resulting mixture was sparged with argon for 5 minutes and then treated with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (53 mg, 0.07 mmol) and copper(I)2-hydroxy-3-methylbenzoate (625 mg, 2.91 mmol). The mixture was then sparged with argon for an additional 5 minutes and then heated to 100°C for 3 hours. The resulting mixture was cooled to RT and passed through diatomaceous earth such as The mixture was filtered and the pad was washed with MeOH (30 mL). The filtrate was concentrated to dryness and purified by FCC (petroleum ether: ethyl acetate = 1:0 to 1:1) to give 6-(3-bromophenyl)-N-(2,4-dimethoxybenzyl)pyrimido[5,4-d]pyrimidin-4-amine (370 mg, 56%) as a yellow solid. MS (ESI): C 21 H 18 The calculated mass of BrN5O2 is 451.1, and the measured m / z is 451.9 [M+H] + .
[1485] Intermediate 24: 6-chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine.
[1486]
[1487] Step A: 5-amino-2-chloro-6-methylpyrimidine-4-carbonitrile. To a solution of 5-amino-2-chloro-6-methylpyrimidine-4-carboxylic acid methyl ester (3.0 g, 17 mmol) and CH3CN (30 mL) were added tetrabutylammonium cyanide (5.0 g, 19 mmol) and 1,4-diazabicyclo[2.2.2]octane (2.8 g, 25 mmol). The resulting mixture was stirred at 50 ° C for 16 h, then cooled to RT, poured into water (30 mL) and extracted with ethyl acetate (50 mL×3). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated to dryness. The resulting residue was purified by FCC (petroleum ether / ethyl acetate=1:0 to 1:1) to give 5-amino-2-chloro-6-methylpyrimidine-4-carbonitrile (1.1 g, 38%) as a yellow solid. MS (ESI): mass calculated for C6H5ClN4: 168.02; m / z found: 168.8 [M+H] + . 1 H NMR (400MHz, CDCl3) δ4.58 (br s, 2H), 2.51 (s, 3H).
[1488] Step B: 6-chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine. To a solution of 5-amino-2-chloro-6-methylpyrimidine-4-carbonitrile (150 mg, 0.89 mmol), formamidine acetate (185 mg, 1.78 mmol) and 1,4-dioxane (3 mL) was added DIPEA (0.7 mL, 4 mmol). The resulting mixture was stirred at 110 ° C for 16 h, then cooled to RT and concentrated to dryness. The resulting residue was purified by FCC (petroleum ether: ethyl acetate = 1:0 to 1:1) to give 6-chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine (106 mg, 61%) as a brown solid. MS (ESI): mass calculated for C7H6ClN5 is 195.03, m / z found is 196.1 [M+H] + .
[1489] Intermediate 25: 6-chloro-N-(2,4-dimethoxybenzyl)-2-methylpyrimido[5,4-d]pyrimidin-4-amine .
[1490]
[1491] Step A: 6-chloro-2-methylpyrimido[5,4-d]pyrimidin-4(3H)-one. A 250 mL three-necked round-bottom flask was charged with ethyl 5-amino-2-chloropyrimidine-4-carboxylate (2.0 g, 9.9 mmol) and CH3CN (70 mL). HCl gas (>1.3 M) was bubbled through the resulting mixture at RT for 0.5 h. The resulting mixture was stirred at 80 ° C for 2 h and then cooled to RT. The resulting solid was separated by filtration, and the filter cake was washed with acetonitrile (20 mL×2) and then dried under reduced pressure to give 6-chloro-2-methylpyrimido[5,4-d]pyrimidin-4(3H)-one (2.0 g). MS (ESI): The mass calculated value for C7H5ClN4O was 196.02. The found value of m / z was 196.8 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ9.22 (s, 1H), 2.40 (s, 3H).
[1492] Step B: 6-chloro-N-(2,4-dimethoxybenzyl)-2-methylpyrimido[5,4-d]pyrimidin-4-amine. To a solution of 6-chloro-2-methylpyrimido[5,4-d]pyrimidin-4(3H)-one (500 mg, 2.54 mmol), DMF (18.0 mg, 0.25 mmol), and DCM (5 mL) was added oxalyl chloride (968 mg, 7.63 mmol). The mixture was stirred at room temperature for 16 h and then concentrated to dryness. The resulting residue was dissolved in THF (5 mL), n-BuOH (1 mL), and DIPEA (3.30 g, 26.0 mmol), and (2,4-dimethoxyphenyl)methanamine (425 mg, 2.54 mmol) was added at room temperature. After 16 h, the mixture was poured into water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The resulting residue was purified by FCC (petroleum ether:ethyl acetate = 10:1 to 1:1) to give 6-chloro-N-(2,4-dimethoxybenzyl)-2-methylpyrimido[5,4-d]pyrimidin-4-amine (350 mg, 40%) as a light yellow solid. MS (ESI): C 16 H 16 The calculated mass of ClN5O2 is 345.10. The measured m / z is 346.1 [M+H] + .
[1493] Intermediate 26: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4-amine .
[1494]
[1495] Step A: methyl 3-amino-4-bromo-6-chloropicolinate. A solution of methyl 3-amino-6-chloropicolinate (1.59 g, 8.51 mmol) in DMF (20 mL) was treated with N-bromosuccinimide (1.62 g, 8.99 mmol) and then heated to 80°C. After 1.5 h, additional N-bromosuccinimide (0.19 g, 1.09 mmol) was added and stirred for 2 h. The resulting mixture was then concentrated to dryness. Ethyl acetate (150 mL) and saturated aqueous NaHCO3 (150 mL) were added to the residue. The organic layer was separated and washed with brine (150 mL x 2). The organic extract was dried over anhydrous (MgSO4), filtered and concentrated to dryness to give methyl 3-amino-4-bromo-6-chloropicolinate (2.2 g, 96%). MS (ESI): mass calculated for C7H6BrClN2O2: 263.9; m / z found: 264.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.59 (s, 1H), 6.40 (br s, 2H), 3.98 (s, 3H).
[1496] Step B: 3-amino-6-chloro-4-methylpicolinic acid methyl ester. A round-bottom flask was charged with 3-amino-4-bromo-6-chloropicolinic acid methyl ester (1.08 g, 4.08 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with dichloromethane) (0.34 g, 0.41 mmol). The vessel was sealed with a septum, evacuated, and then purged with nitrogen three times. The flask was charged with degassed 1,4-dioxane (25 mL), followed by degassed K2CO3 (12 mL, 2M H2O solution) and trimethylcyclotriboroxane (0.61 mL, 4.32 mmol). The resulting mixture was heated to 80°C. After 1 h, the mixture was cooled to RT, diluted with ethyl acetate (150 mL) and washed with brine (150 mL×2). The organic extract was dried over anhydrous MgSO4, filtered and concentrated to dryness. The residue was purified by FCC to give methyl 3-amino-6-chloro-4-methylpicolinate (422 mg, 52%). MS (ESI): mass calculated for C8H9ClN2O2: 200.0; m / z found: 201.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.16(s,1H),5.91(br s,2H),3.96(s,3H),2.22(s,3H).
[1497] Step C: Methyl 3-amino-4-methyl-6-(3-(trimethylsilyl)phenyl)picolinate. A flask was charged with methyl 3-amino-6-chloro-4-methylpicolinate (0.41 g, 2.06 mmol), (3-(trimethylsilyl)phenyl)boronic acid (0.52 g, 2.67 mmol), and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.16 g, 0.20 mmol). The vessel was sealed with a septum, evacuated, and then purged with nitrogen three times. The flask was charged with degassed 1,4-dioxane (10 mL) followed by degassed KCO (5 mL, 2M solution in H2O) and then heated to 80°C. After 1 h, the mixture was cooled to RT, diluted with ethyl acetate (150 mL) and washed with brine (150 mL x 2). The organic extract was dried over anhydrous (MgSO4), filtered and concentrated to dryness. The residue was purified by FCC to give methyl 3-amino-4-methyl-6-(3-(trimethylsilyl)phenyl)picolinate (600 mg, 93%). MS (ESI): C 17 H 22 The calculated mass of N2O2Si is 314.2; the measured m / z is 315.1 [M+H] + . 1 H NMR(400MHz, CDCl3)δ8.00(s,1H),7.91-7.86(m,1H),7.60(s,1H),7.52-7.48(m ,1H),7.42(t,J=7.5Hz,1H),5.88(s,2H),3.99(s,3H),2.30(s,3H),0.31(s,9H).
[1498] Step D: methyl 3-amino-6-(3-iodophenyl)-4-methylpicolinate. To a solution of methyl 3-amino-4-methyl-6-(3-(trimethylsilyl)phenyl)picolinate (0.5 g, 1.6 mmol) in DCM (13 mL) was added iodine monochloride (8.0 mL, 1 M solution in DCM) at 0°C. The resulting mixture was warmed to RT. After 2 h, the mixture was concentrated and purified directly by FCC to give methyl 3-amino-6-(3-iodophenyl)-4-methylpicolinate (135 mg, 23%). MS (ESI): C 14 H 13 The calculated mass of IN2O2 is 368.00; the found m / z is 369.0 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.27 (s, 1H), 7.95-7.80 (m, 1H), 7.66 (d, J = 7.3Hz, 1H), 7.56 (s, 1H), 7.22-7.08 (m, 1H), 5.93 (br s,2H),4.00(s,3H),2.28(s,3H).
[1499] Step E: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4(3H)-one. A mixture of methyl 3-amino-6-(3-iodophenyl)-4-methylpicolinate (0.14 g, 0.37 mmol) in THF (2 mL) was treated with formamide (4 mL) and microwaved at 175 °C for 30 min and then at 200 °C for another 30 min. The resulting mixture was diluted with H2O (10 mL) and the resulting solid was collected by filtration and dried under vacuum to give 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4(3H)-one (75 mg, 56%). MS (ESI): C 14 H 10 The calculated mass of IN3O is 362.99; the found m / z is 364.0 [M+H] + .
[1500] Step F: 4-chloro-6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidine. A suspension of 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4(3H)-one (0.14 g, 0.39 mmol) in phosphorus oxychloride (3 mL) was treated with DIPEA (0.15 mL) and microwave irradiated at 100 ° C for 30 min. The resulting mixture was then concentrated to dryness. The residue was dissolved in DCM (10 mL) and DIPEA (0.5 mL). The resulting mixture was concentrated to dryness, triturated with MeCN (15 mL), and the resulting solid was collected by filtration to give chloro-6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidine (126 mg, 83%). MS (ESI): C 14 The calculated mass of H9ClIN3 is 380.95; the found m / z is 382.0 [M+H] + .
[1501] Step G: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4-amine. A solution of 4-chloro-6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4-amine (0.13 g, 0.33 mmol) and NH3 (3 mL, 2MMeOH solution) was microwave irradiated at 100 ° C for 30 min. The resulting mixture was concentrated to dryness and purified by FCC to give 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin-4-amine (53 mg, 44%). MS (ESI): C 14 The calculated mass of H9ClIN3 is 362.00; the found m / z is 363.0 [M+H] + .
[1502] Intermediate 27: (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (4-(trifluoromethoxy)phenyl)ethynyl)pyrrolidin-2-one.
[1503]
[1504] Step A: 2-(5-bromo-2-(trifluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. A mixture of (5-bromo-2-(trifluoromethoxy)phenyl)boronic acid (29.5 g, 104 mmol) and 2,3-dimethylbutane-2,3-diol (12.4 g, 105 mmol) in THF (260 mL) was purged with N2 and then stirred under nitrogen at 25°C for 36 h. The reaction mixture was concentrated to dryness to give the title compound 2-(5-bromo-2-(trifluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (38.0 g, 95.0%) as a white solid. MS (ESI): C 13 H 15 The calculated mass of BBrF3O3 is 366.02; the found m / z is 342.1 [M+H] + .
[1505] Step B: (R)-3-Hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethoxy)phenyl)ethynyl)pyrrolidin-2-one. A 1 L round-bottom flask was charged with Pd(PPh3)4 (7.9 g, 6.8 mmol), 2-[5-bromo-2-(trifluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (25 g, 68 mmol), (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (14.2 g, 102.2 mmol), CuI (2.6 g, 14 mmol), tri-n-butylphosphonium tetrafluoroborate (1.9 g, 6.8 mmol), piperidine (20 mL, 204 mmol) and DMF (300 mL). The reaction mixture was degassed with N2 and stirred at 60°C under nitrogen for 16 h. The reaction mixture was diluted with water (1500 mL) and extracted with EtOAc (2×200 mL) and DCM (5×100 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated to dryness. The crude residue was purified by FCC (0-40% ethyl acetate / petroleum ether) and then by preparative HPLC (WelchXtimate C18 10 μm, 250×50 mm; mobile phase: [water (0.1% TFA)-ACN]; B%: 30%-66%, 20 min. Detection, UVλ=220-254 nM) to give (R)-3-hydroxy-1-methyl-3-[2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethoxy)phenyl]ethynyl]pyrrolidin-2-one (4.3 g, 14%) as a brown solid. MS (ESI): C 20 H 23 The calculated mass of BF3NO5 is 425.16; the found m / z is 426.0 [M+H] + . 1 HNMR(400MHz, CDCl3) δ7.80(d,J=2.2Hz,1H),7.45(dd,J=8.5,2.3Hz,1H),7.10(d,J=7.8Hz,1H),3.4 7-3.36(m,1H),3.35-3.23(m,1H),2.89(s,3H),2.64-2.46(m,1H),2.37-2.20(m,1H),1.27(s,12H).
[1506] Intermediate 28: 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8-amine.
[1507]
[1508] Step A: tert-Butyl (2-chloropyridin-3-yl)carbamate. A 2L 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was charged with a solution of 2-chloropyridin-3-amine (60 g, 467 mmol) in THF (700 mL). This was followed by the addition of sodium bis(trimethylsilyl)amide (516 mL, 1027 mmol, 0.5 M THF solution) dropwise at -10°C with stirring. The mixture was stirred for 30 min at -10°C. A solution of Boc2O (112 g, 516 mmol) in THF (100 mL) was added dropwise at -10°C with stirring. The resulting solution was stirred at -10°C for 1 h and subsequently partitioned with hydrogen chloride solution (500 mL, 2N). The resulting mixture was extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (200 mL x 3), then dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC to give tert-butyl N-(2-chloropyridin-3-yl)carbamate (89 g, 83%) as an off-white solid.
[1509] Step B: tert-butyl (2-chloro-4-formylpyridin-3-yl) carbamate. A 4-neck round-bottom flask of 3L purged and maintained with an inert atmosphere of nitrogen was charged with a solution of tert-butyl N-(2-chloropyridin-3-yl) carbamate (105g, 459mmol) in THF (1600mL) and tetramethylethylenediamine (118g, 1.01mol). The resulting solution was cooled to -78°C under stirring and n-BuLi (405mL, 2.5M) was added dropwise. The solution was warmed to -40°C and stirred for 1h. The resulting solution was cooled to -78°C, N,N-dimethylformamide (84g, 1.2mol) was added dropwise and stirred for 1h. The resulting solution was distributed with a saturated ammonium chloride solution (500mL) and extracted with ethyl acetate (200mL×3). The combined organic layers were washed with brine (200 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC to give tert-butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate (75 g, 64%) as a light yellow solid.
[1510] Step C: 3-amino-2-chloroisonicotinaldehyde. A 3L 4-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was charged with a solution of tert-butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate (75g, 292mmol) in DCM (1500mL). The resulting solution was cooled to 0°C and trifluoroacetic acid (300mL) was added dropwise with stirring. The resulting solution was warmed to RT, stirred for 12h, and then partitioned with a saturated sodium carbonate (800mL) solution. The mixture was extracted with DCM (200mL×2), and the combined organic layers were then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was suspended in n-hexane (200mL) and stirred for 20min. The resulting solid was collected by filtration to obtain 3-amino-2-chloropyridine-4-carboxaldehyde (30g, 66%) as a yellow solid. MS (ESI): mass calculated for C6H5ClN2O: 156.01; m / z found: 157 [M+H] + . 1 H NMR (300MHz, CDCl3) δ9.99 (s, 1H), 7.89 (d, J = 4.8Hz, 1H), 7.38 (d, J = 5.1HZ, 1H), 6.56 (br s, 2H).
[1511] Step D: 2-(3-bromophenyl)-8-chloropyrido[3,4-d]pyrimidine. A 250 mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was charged with a solution of 3-amino-2-chloropyridine-4-carboxaldehyde (28 g, 179 mmol) in water (56 mL), (3-bromophenyl)methylamine (83 g, 446 mmol), tert-butyl hydroperoxide (32 g, 359 mmol), pyridine (1.5 g, 19 mmol) and I2 (4.6 g, 18 mmol). The resulting solution was heated to 90 ° C. After 12 h, the resulting mixture was cooled to RT and ethyl acetate (500 mL) was added. The resulting mixture was washed with brine (100 mL×3), and the organic layer was then dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC to give 2-(3-bromophenyl)-8-chloropyrido[3,4-d]pyrimidine (18 g, 31%) as a pale yellow solid.
[1512] Step E: 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8-amine. A 250 mL sealed tube was charged with 2-(3-bromophenyl)-8-chloropyrido[3,4-d]pyrimidine (18 g, 56 mmol) and NH3 in IPA (180 mL, 2 M). The resulting solution was heated to 145 ° C. After 12 h, the resulting mixture was cooled to RT and concentrated to dryness. The resulting residue was diluted with DCM (1000 mL), washed with brine (100 mL×3), and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting solid was recrystallized from ethyl acetate and the solid was collected by filtration to give 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8-amine (10.1 g, 60%) as a light brown solid. MS (ESI): C 13 The calculated mass of H9BrN4 is 300.0; the found m / z is 301.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ9.61(s,1H),8.94(s,1H),8.69(d,J=8.1Hz,1H),8.35(brs,2H),7 .95(d,J=6.1Hz,1H),7.78(d,J=7.8Hz,1H),7.54(t,J=7.9Hz,1H),7.13(d,J=6.0Hz,1H).
[1513] Intermediate 29: 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one.
[1514]
[1515] A flask was charged with 2-(3-bromophenyl)-8-chloropyrido[3,4-d]pyrimidine [Intermediate 28: Step D, 2.0 g, 6.2 mmol], hydrogen chloride (10 mL, 6N) and THF (10 mL). The resulting solution was stirred at 80°C for 2 h. The resulting mixture was cooled to RT and the pH was adjusted to 8 with saturated aqueous sodium bicarbonate solution. The resulting mixture was extracted with ethyl acetate (50 mL×3) and the combined organic layers were concentrated to dryness to give 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one (1.6 g, 85%) as a light yellow solid. MS (ESI): C 13 The calculated mass of H8BrN3O is 301.0; the found m / z is 302.0 [M+H] + .
[1516] Intermediate 30: (R)-2-thiazol-2-ylbut-3-yn-2-ol .
[1517]
[1518] Under an inert atmosphere of nitrogen, a 5 L, 4-necked round-bottom flask was charged with a solution of ethynylmagnesium bromide (1889 mL, 0.5 M THF solution). To this solution, 1-(1,3-thiazol-2-yl)ethan-1-one (60 g, 472 mmol) was added dropwise with stirring at room temperature. After 2 h, the resulting solution was partitioned with saturated aqueous ammonium chloride (900 mL) and water (600 mL). The resulting mixture was extracted with ethyl acetate (600 mL x 3), and the combined organic layers were washed with brine (600 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude residues of the (R) and (S) enantiomers (65 g, 90%) were further purified by chiral preparative SFC (CHIRALPAK IG 4.6×50 mm, 3 μm; mobile phase, CO₂ (80%), MeOH (0.1% DEA); detector, λ=254 nm) to afford (R)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol (21 g, 32%, >97% ee) as a yellow solid and (S)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol (Intermediate 31, 21 g, 32%) as a yellow solid. Data for (R)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol: MS (ESI): mass calculated for CₐHₐNOS 153.0; m / z found 153.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.78 (d, J = 3.3 Hz, 1H), 7.36 (d, J = 3.3 Hz, 1H), 3.66 (s, 1H), 2.72 (s, 1H), 1.98 (s, 3H). [α] 20 D =-34.6.5 (c=0.54, MeOH).
[1519] Intermediate 31: (S)-2-thiazol-2-ylbut-3-yn-2-ol .
[1520]
[1521] Chiral separation described in Intermediate 30 provided (S)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol (21 g, 32%, >97% ee) as a yellow solid. MS (ESI): mass calculated for C7H7NOS 153.0; m / z found 153.9 [M+H] + . 1H NMR (400MHz, CDCl3) δ7.78 (d, J = 3.3 Hz, 1H), 7.36 (d, J = 3.3 Hz, 1H), 3.66 (s, 1H), 2.72 (s, 1H), 1.98 (s, 3H). [α] 20 D =+35.3 (c=0.51, MeOH).
[1522] Intermediate 32: (R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol .
[1523]
[1524] Ethynylmagnesium bromide (480 mL, 0.5 M THF solution) was placed in a 1 L round-bottom flask purged and maintained with an inert atmosphere of nitrogen. The container was cooled to 0 ° C and a solution of 1- (5-methyl-1,2-oxazol-3-yl) ethyl-1-one (20 g, 160 mmol) in THF (200 mL) was added dropwise with stirring. The resulting solution was warmed and stirred at 25 ° C for 2 h. The resulting solution was cooled to 0 ° C and a saturated aqueous ammonium chloride solution (300 mL) was added, followed by water (200 mL). The resulting mixture was extracted with ethyl acetate (200 mL × 2), and the combined organic layers were washed with brine (200 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by FCC (gradient 0:1 to 1:10, ethyl acetate:petroleum ether) to give racemic 2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (19.7 g, 82%) as a yellow oil. 18 g of the obtained material was further purified by preparative chiral SFC (Phenomenex Lux 5u cellulose-4, 5×25 cm, 5 μm; mobile phase, CO2 (70%), IPA:HEX=1:1 (30%); detection, λ=220 nm) to give (R)-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (5.1 g, 28%, >97% ee) as a yellow solid and (S)-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (intermediate 33, 5.1 g, 28%, >97% ee) as a yellow solid. Data for (R)-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol: MS (ESI): mass calculated for C8H9NO2: 151.1; m / z found: 152.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ6.36 (s, 1H), 6.25 (d, J = 0.6Hz, 1H), 3.51 (s, 1H), 2.38 (s, 3H), 1.67 (s, 3H). [α] 20D =-11.3 (c=0.51, MeOH).
[1525] Intermediate 33: (S)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol .
[1526]
[1527] Chiral separation described in Intermediate 32 provided (S)-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (5.1 g, 28%, >97% ee) as a yellow solid. MS (ESI): mass calculated for CHNO 151.1; m / z found 152.0 [M+H]. + . 1 H NMR (400MHz, DMSO-d6) δ6.36 (s, 1H), 6.25 (d, J = 0.6Hz, 1H), 3.51 (s, 1H), 2.38 (s, 3H), 1.67 (s, 3H). [α] 20 D =+8.27 (c=0.54, MeOH).
[1528] Intermediate 34: 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine.
[1529]
[1530] Step A: tert-Butyl (2-chloro-4-(1-hydroxyethyl)pyridin-3-yl)carbamate. Into a 500 mL 4-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a THF (200 mL) solution of tert-butyl N-(2-chloropyridin-3-yl)carbamate (20 g, 87 mmol) and TMEDA (22 g, 191 mmol). The resulting solution was cooled to -78 ° C, followed by dropwise addition of n-BuLi (76.8 mL, 192 mmol). The resulting solution was warmed to -30 ° C and stirred for 30 min, cooled to -78 ° C, and then a THF solution of acetaldehyde (43.6 mL, 5 M) was added. The resulting solution was stirred at -78 ° C for 30 min. The resulting solution was warmed to 0 ° C, followed by addition of a saturated aqueous ammonium chloride solution (300 mL). The resulting solution was extracted with ethyl acetate (500 mL × 2), and the combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by FCC (1:3, ethyl acetate / petroleum ether) to give tert-butyl N-[2-chloro-4-(1-hydroxyethyl)pyridin-3-yl]carbamate (21 g, 88%) as a white solid.
[1531] Step B: (4-acetyl-2-chloropyridin-3-yl) tert-butyl carbamate.To the 3-neck round-bottom flask of 500mL purged and maintained with the inert atmosphere of nitrogen, N-[2-chloro-4-(1-hydroxyethyl) pyridin-3-yl] tert-butyl carbamate (21g, 77mmol), DMSO (210mL) and 2-iodobenzoic acid (43.2g, 154mmol) are added. The resulting solution is stirred for 3h at RT, then distributed with water (500mL). The resulting mixture is extracted with ethyl acetate (500mL×2). The combined organic layer is washed with salt water (500mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. This obtains tert-butyl N-(4-acetyl-2-chloropyridin-3-yl) carbamate (18g, 86%) as a yellow solid, which is directly used in the next step.
[1532] Step C: 1-(3-amino-2-chloropyridin-4-yl) second-1-one. Under RT, to the 3-neck round-bottom flask of 500mL that is purged and maintained with the inert atmosphere of nitrogen, add N-(4-acetyl-2-chloropyridin-3-yl) solution of tert-butyl carbamate (18g, 66mmol) in DCM (180mL) and trifluoroacetic acid (90mL). After 12h, the obtained mixture is concentrated to dryness, and the pH value of the residue is adjusted to 7 with saturated sodium bicarbonate aqueous solution. The obtained mixture is extracted with ethyl acetate (500mL×2). The combined organic layer is washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. This obtains 1-(3-amino-2-chloropyridin-4-yl) second-1-one (8.5g, 75%) as a yellow solid, which is directly used in the next step.
[1533] Step D: N-(4-acetyl-2-chloropyridin-3-yl)-3-iodobenzamide. To a 250 mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was added a solution of 1-(3-amino-2-chloropyridin-4-yl)ethan-1-one (6 g, 35 mmol) in 1,4-dioxane (240 mL), 3-iodobenzoyl chloride (19 g, 70 mmol) and DIEA (9.1 g, 70 mmol). The resulting solution was heated at 110 ° C. After 12 h, the resulting solution was cooled and water (300 mL) was added. The resulting mixture was extracted with ethyl acetate (300 mL×2). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give N-(4-acetyl-2-chloropyridin-3-yl)-3-iodobenzamide (9.3 g, 66%) as a yellow solid.
[1534] Step E: 8-chloro-2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidine. Into a 40 mL 3-necked round-bottom flask was placed N-(4-acetyl-2-chloropyridin-3-yl)-3-iodobenzamide (1.9 g, 4.7 mmol) and a 25 mL, 2 M solution of NH3 in IPA. The resulting solution was heated at 90°C. After 2 h, the resulting mixture was cooled, filtered, and the collected solid was washed with IPA (50 mL) to give 8-chloro-2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidine (6.2 g, 70%) as a yellow solid.
[1535] Step F: 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine. Into a 300 mL pressure tank reactor was placed 8-chloro-2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidine (6.2 g, 16 mmol), NH3 in IPA (120 mL, 2 M) and condensed ammonia (60 mL). The resulting solution was stirred at 145 ° C in an autoclave. After 12 h, the vessel was cooled to RT and the solid was collected by filtration. The resulting solid was washed with MeOH (100 mL) and dried to give 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine (3.7 g, 63%) as a red solid. MS (ESI): C 14 H 11 The calculated mass of IN4 is 362.0; the observed m / z is 363.0 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ9.03(s,1H),8.70(d,J=8.1Hz,1H),7.99(d,J=5.7Hz,1H),7.90 (d,J=7.8Hz,1H),7.44(s,2H),7.35(t,J=7.8Hz,1H),7.07(d,J=5.7Hz,1H),2.87(s,3H).
[1536] Intermediate 35: 2-(3-bromophenyl)-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8-amine.
[1537]
[1538] Step A: tert-butyl (2-chloropyridine-3-yl) carbamate. Into the 3-neck round-bottom flask of 2L purged and maintained with the inert atmosphere of nitrogen, put into THF (500mL) solution of 2-chloropyridine-3-amine (50g, 389mmol). Make the resulting solution cool -10 ℃, then add bis (trimethylsilyl) sodium amide (430mL, 856mmol), keep 30min. After this, drip (Boc) THF (200mL) solution of O (94g, 429mmol), and the resulting solution is stirred at -10 ℃. After 2h, the pH of the resulting solution is adjusted to 7 with hydrogen chloride (2N) and extracted with ethyl acetate (1000mL×2). The combined organic layer is washed with salt water (1000mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by FCC (1:10, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloropyridin-3-yl)carbamate (70 g, 79%) as a white solid.
[1539] Step B: tert-Butyl N-[2-chloro-4-(2,2,2-trifluoro-1,1-dihydroxyethyl)pyridin-3-yl]carbamate. Into a 500 mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl N-(2-chloropyridin-3-yl)carbamate (20 g, 87 mmol), TMEDA (22 g, 192 mmol), and THF (200 mL). This was followed by the dropwise addition of n-BuLi (76.8 mL, 1.5 M) at -78°C with stirring. The mixture was stirred at -78°C for 30 min, then at -40°C for 30 min. To the resulting mixture was added dropwise 2,2,2-trifluoro-N-methoxy-N-methylacetamide (34 g, 218 mmol) at -78°C with stirring. The resulting mixture was stirred at -40 ° C for 30 min and then distributed with saturated aqueous ammonium chloride solution (100 mL). The resulting mixture was extracted with ethyl acetate (200 mL × 2). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1: 10, ethyl acetate / petroleum ether) to obtain tert-butyl N- [2- chloro -4- (2,2,2- trifluoro -1,1- dihydroxyethyl) pyridin-3-yl] carbamate (26 g, 87%) as a white solid.
[1540] Step C: 1-(3-amino-2-chloropyridin-4-yl)-2,2,2-trifluoroethane-1,1-diol as trifluoroacetate. To a 1 L 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was added tert-butyl N-[2-chloro-4-(2,2,2-trifluoro-1,1-dihydroxyethyl)pyridin-3-yl]carbamate (26 g, 76 mmol), trifluoroacetic acid (130 mL) and DCM (260 mL) at RT. After 4 h, the resulting mixture was concentrated to dryness to give 1-(3-amino-2-chloropyridin-4-yl)-2,2,2-trifluoroethane-1,1-diol, trifluoroacetate (28 g, crude) as a yellow solid.
[1541] Step D: 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)-1H,2H-pyrido[3,4-d]pyrimidine. A 500 mL pressure tank reactor was charged with 1-(3-amino-2-chloropyridin-4-yl)-2,2,2-trifluoroethane-1,1-diol as the trifluoroacetate salt (10 g, 28 mmol), 3-bromobenzaldehyde (38 g, 206 mmol), 30% aqueous ammonia (12 g), and ACN (200 mL). The resulting solution was stirred at 52°C for 16 h, then the temperature was raised to 90°C and maintained for an additional 16 h. The resulting mixture was concentrated to dryness and purified by FCC (1:5, ethyl acetate / petroleum ether) to afford 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)-1H,2H-pyrido[3,4-d]pyrimidine (13 g, crude) as a yellow solid.
[1542] Step E: 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)pyrido[3,4-d]pyrimidine. Into a 250 mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)-1H,2H-pyrido[3,4-d]pyrimidine (12 g, 31 mmol), CH3CN (120 mL) and 2,3-dichloro-5,6-dicyanobenzoquinone (6.96 g). The resulting solution was stirred at 25 ° C for 2 h. The pH of the solution was adjusted to 8 using saturated aqueous sodium bicarbonate solution. The resulting mixture was extracted with DCM (100 mL×3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:10, ethyl acetate / petroleum ether) to give 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)pyrido[3,4-d]pyrimidine (5.5 g, 46%) as a yellow solid.
[1543] Step F: 2-(3-bromophenyl)-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8-amine. Into a 250 mL pressure tank reactor was placed 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)pyrido[3,4-d]pyrimidine (4.5 g, 12 mmol) and NH3 in IPA (90 mL, 2 M). The resulting solution was stirred at 145 °C for 16 h. The reaction mixture was cooled and the solid was collected by filtration. MeOH (30 mL) was added to the solid and the mixture was stirred for 1 h. The solid was collected by filtration to give 2-(3-bromophenyl)-4-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8-amine (3.9 g, 91%) as a yellow solid. MS (ESI): C 14 The calculated mass of H8BrF3N4 is 367.9; the found m / z is 369.0 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.92(s,1H),8.66(d,J=8.1Hz,1H),8.12(d,J=6.0Hz,1H),7.91(br s, 2H), 7.79 (d, J = 7.2Hz, 1H), 7.56 (t, J = 7.8Hz, 1H), 7.00-6.97 (m, 1H). 19 F NMR (282MHz, DMSO-d6, ppm): δ-65.26.
[1544] Intermediate 36: 2-(3-bromophenyl)-5-methylpyrido[3,4-d]pyrimidin-8-amine .
[1545]
[1546] Step A: tert-butyl N-(2-chloro-5-methoxypyridin-3-yl)carbamate. Into the 3-neck round-bottom flask of 1L purged and maintained with the inert atmosphere of nitrogen, put into THF (190mL) solution of 2-chloro-5-methylpyridine-3-amine (19g, 133mmol). Make the resulting solution cool -10 DEG C, then add bis(trimethylsilyl) sodium amide (147mL, 2M), keep 30min. After this, (Boc) is added dropwise THF (320mL) solution of O (32g, 147mmol), and the resulting solution is stirred at -10 DEG C. After 2h, the pH of the resulting solution is adjusted to 7 with hydrogen chloride (2N) and extracted with ethyl acetate (500mL×2). The combined organic layer is washed with brine (500mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by FCC (1:11, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloro-5-methylpyridin-3-yl)carbamate (32 g, 99%) as a pale yellow solid.
[1547] Step B: tert-butyl N-(2-chloro-4-formyl-5-methoxypyridin-3-yl)carbamate. Into a 500mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, a solution of tert-butyl N-(2-chloro-5-methylpyridin-3-yl)carbamate (20g, 82mmol) in THF (200mL) and TMEDA (21g, 181mmol) was placed. The container was cooled to -78°C and n-BuLi (72mL, 2.5M) was added dropwise. The resulting solution was stirred at -35°C for 30min. The resulting solution was cooled to -78°C and N,N-dimethylformamide (15g, 205mmol) was added dropwise while stirring. After 30min, saturated aqueous ammonium chloride solution (200mL) was added, and the resulting mixture was extracted with ethyl acetate (500mL×2). The combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloro-4-formyl-5-methylpyridin-3-yl)carbamate (11.9 g, 53%) as a yellow solid.
[1548] Step C: 3-amino-2-chloro-5-methylpyridine-4-carboxaldehyde. Under RT, to the 500mL 3-neck round-bottom flask purged and maintained with the inert atmosphere of nitrogen, add N-(2-chloro-4-formyl-5-methylpyridin-3-yl)carbamic acid tert-butyl ester (12g, 44mmol) in DCM (120mL) and trifluoroacetic acid (60mL). After 12h, the obtained mixture is concentrated to dryness, and the residue is diluted with saturated sodium bicarbonate aqueous solution until pH=7. The obtained mixture is extracted with ethyl acetate (500mL×2). The combined organic layer is washed with brine (500mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness to obtain 3-amino-2-chloro-5-methylpyridine-4-carboxaldehyde (7g, 93%) as a yellow solid.
[1549] Step D: 2-(3-bromophenyl)-8-chloro-5-methylpyrido[3,4-d]pyrimidine. Into a 50 mL sealed tube was placed 3-amino-2-chloro-5-methylpyridine-4-carbaldehyde (1.0 g, 5.8 mmol), 3-bromobenzene-1-carboxamidine hydrochloride (1.7 g, 7.1 mmol), tert-butanol (20 mL), TEA (0.6 g) and pyridine (1.2 g). The resulting solution was stirred at 90 ° C for 14 h. This process was repeated 5 times, and the combined reaction mixture was cooled to room temperature and diluted with water (500 mL). The resulting mixture was extracted with ethyl acetate (500 mL×3). The combined organic layers were washed with hydrogen chloride (500 mL, 1N) and brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (3:10, ethyl acetate / petroleum ether) to give 2-(3-bromophenyl)-8-chloro-5-methylpyrido[3,4-d]pyrimidine (4.2 g, 35%) as a yellow solid.
[1550] Step E: 2-(3-bromophenyl)-5-methylpyrido[3,4-d]pyrimidin-8-amine. Into a 250 mL pressure tank reactor was placed 2-(3-bromophenyl)-8-chloro-5-methylpyrido[3,4-d]pyrimidine (4.2 g, 13 mmol) and NH3 in IPA (84 mL, 2 M). The resulting solution was stirred at 145 °C in an oil bath for 16 h. The reaction mixture was cooled, concentrated to dryness, and the solid was collected by filtration. The solid was added to a 250 mL pressure tank reactor and NH3 in MeOH (84 mL, 7 N), and the resulting mixture was stirred at 145 °C in an oil bath for 16 h. The reaction mixture was cooled, and the solid was collected by filtration. The solid was added to Et2O (30 mL), the mixture was stirred for 1 h, and the solid was collected by filtration to give 2-(3-bromophenyl)-5-methylpyrido[3,4-d]pyrimidin-8-amine (2.5 g, 63%) as a yellow solid. MS (ESI): C 14 H 11 The calculated mass of BrN4 is 314.0; the measured m / z is 315.0 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ9.62 (s, 1H), 8.90 (s, 1H), 8.68 (d, J = 7.8Hz, 1H), 7.83 ( s, 1H), 7.75 (d, J = 8.7Hz, 1H), 7.53 (t, J = 7.8Hz, 1H), 7.29 (s, 2H), 2.46 (s, 3H).
[1551] Intermediate 37: 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidin-8-amine.
[1552]
[1553] Step A: tert-butyl N-(2-chloropyridine-3-yl)carbamate.Into the 3-neck round-bottom flask of 2L purged and maintained with the inert atmosphere of nitrogen, put into THF (500mL) solution of 2-chloropyridine-3-amine (50g, 389mmol).The resulting solution is cooled to -10 ℃, then bis(trimethylsilyl) sodium amide (430mL, 2M) is added, kept for 30min.After this, (Boc) is added dropwise THF (200mL) solution of O (94g, 428mmol), and the resulting solution is stirred at -10 ℃.After 2h, the pH of the resulting solution is adjusted to 7 with hydrogen chloride (2N) and extracted with ethyl acetate (1000mL×2).The organic layer merged is washed with salt water (1000mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by FCC (1:11, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloropyridin-3-yl)carbamate (80 g, 90%) as a white solid.
[1554] Step B: tert-butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate. Into a 500mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, a solution of tert-butyl N-(2-chloropyridin-3-yl)carbamate (20g, 87mmol) in THF (200mL) and TMEDA (22.3g, 191mmol) was placed. The container was cooled to -78°C and n-BuLi (78mL, 2.5M) was added dropwise. The resulting solution was stirred at -35°C for 30min. The resulting solution was cooled to -78°C and N,N-dimethylformamide (16g, 218mmol) was added dropwise while stirring. After 30min, saturated aqueous ammonium chloride solution (500mL) was added, and the resulting mixture was extracted with ethyl acetate (500mL×2). The combined organic layer was washed with brine (500mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate (28 g, 82%) as a white solid.
[1555] Step C: 3-amino-2-chloropyridine-4-carboxaldehyde. Into a 1000mL 3-neck round-bottom flask was placed a solution of tert-butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate (55g, 214mmol) in DCM (550mL) and trifluoroacetic acid (270mL). After 12h, the resulting mixture was concentrated to dryness, and the residue was diluted with saturated sodium bicarbonate aqueous solution until pH=7. The resulting mixture was extracted with ethyl acetate (500mL×2). The combined organic layer was washed with brine (500mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:3, ethyl acetate / petroleum ether) to obtain 3-amino-2-chloropyridine-4-carboxaldehyde (19g, 57%) as a yellow solid.
[1556] Step D: 3-amino-6-bromo-2-chloropyridine-4-carboxaldehyde. Into a 500 mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 3-amino-2-chloropyridine-4-carboxaldehyde (19 g, 121 mmol) in N,N-dimethylformamide (190 mL) and boryl (sulfonyl) amine (24 g, 404 mmol) at RT. After 1 h, the resulting mixture was partitioned with ice water (1000 mL) and the solid was collected by filtration to give 3-amino-6-bromo-2-chloropyridine-4-carboxaldehyde (25 g, 87%) as a yellow solid.
[1557] Step E: 3-amino-2-chloro-6-methylpyridine-4-carboxaldehyde. Into a 500mL 3-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 3-amino-6-bromo-2-chloropyridine-4-carboxaldehyde (25g, 106mmol) in 1,4-dioxane (250mL), water (50mL), methylboric acid (19g, 319mmol), potassium carbonate (71g, 509mmol) and Pd(dppf)Cl2 (3.9g, 5.3mmol). The resulting solution was stirred at 90°C. After 12h, the reaction mixture was cooled to RT and water (300mL) was added. The resulting mixture was extracted with ethyl acetate (300mL×2). The combined organic layers were washed with brine (200mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give 2-chloro-6-methylpyridine-4-carbaldehyde (6.6 g, 36%) as a yellow solid.
[1558] Step F: 8-chloro-2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidine. A 40 mL sealed tube was charged with a solution of 3-amino-2-chloro-6-methylpyridine-4-carboxaldehyde (1.3 g, 7.6 mmol) in tert-butanol (26 mL), 3-iodobenzene-1-formamidine (2.3 g, 9.2 mmol), TEA (0.8 g, 7.6 mmol) and pyridine (1.5 g, 19 mmol). The resulting solution was stirred at 90 ° C. After 12 h, the resulting mixture was cooled to RT and water (40 mL) was added. The resulting mixture was extracted with ethyl acetate (60 mL×3). The combined organic layers were washed with hydrogen chloride (50 mL, 2N) and brine (50 mL). The resulting organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by FCC (1:10, ethyl acetate / petroleum ether) to give 8-chloro-2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidine (1.2 g, 33%) as a yellow solid.
[1559] Step G: 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidin-8-amine. Into a 300 mL vial purged and maintained with an inert atmosphere of nitrogen was placed 8-chloro-2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidine (4.8 g, 13 mmol), NH3 in IPA (90 mL, 2 M) and NH4OH (45 mL, 28% NH3 in water). The resulting solution was stirred at 145°C. After 12 h, the mixture was cooled, the solid was collected by filtration, and the solid (3.5 g) was further purified by preparative HPLC to give 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidin-8-amine (2 g, 45%) as a yellow solid. MS (ESI): C 14 H 11 The calculated mass of IN4 is 362.2; the found m / z is 363.0 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ9.42(s,1H),9.03(s,1H),8.67(d,J=8.1Hz,1H),7.89(d,J=7.8Hz,1H),7.55(br s, 2H), 7.35 (t, J = 5.7Hz, 1H), 6.86 (s, 1H), 2.42 (s, 3H).
[1560] Intermediate 38: (R)-7-Ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol .
[1561]
[1562] Step A: 6,7-dihydro-5H-cyclopenta[b]pyridine-1-oxide. To a stirred solution of (1Z)-N-(cyclopent-1-en-1-yl)ethane-1-imine (250 g, 2.29 mol) in DCM (5000 mL) was added portionwise m-chloroperbenzoic acid (454 g, 2.10 mol, 80% purity) at 0°C under nitrogen. The resulting mixture was stirred at room temperature under nitrogen for 2 h. The resulting mixture was concentrated to dryness, and the residue was purified by FCC (20:1, CHCl / MeOH) to give 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (220 g, 71.08%) as a white solid. MS (ESI): mass calculated for CHNO: 135.0; m / z found: 136.2 [M+H]. + .
[1563] Step B: 6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate. A solution of 6,7-dihydro-5H-cyclopenta[b]pyridin-1-oxide (220 g, 1.63 mol) in AcO (2 L) was stirred at 100 ° C. under a nitrogen atmosphere for 2 h. The resulting mixture was concentrated to dryness and purified by FCC (3:1, petroleum ether / ethyl acetate) to give 6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (215 g, 74.5%) as an orange oil.
[1564] Step C: 6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol. To a stirred solution of 6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (215 g, 1.21 mol) in EtOH (500 mL) was added dropwise a solution of KOH (68.1 g, 1.21 mol) in EtOH (1.2 L) at 0 ° C under a nitrogen atmosphere. The resulting mixture was stirred at RT under a nitrogen atmosphere for 1 h. The resulting mixture was concentrated to one-third of its volume and extracted with DCM (1 L x 3). The combined organic layers were washed with brine (1 L), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The resulting residue was purified by FCC (20:1, CH2Cl2 / MeOH) to give 5H,6H,7H-cyclopenta[b]pyridin-7-ol (140 g, 85.3%) as a light brown solid.
[1565] Step D: 5,6-dihydro-7H-cyclopenta[b]pyridin-7-one. To a stirred solution of 6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (140 g, 1.04 mol) in DCM (1.5 L) was added dioxin (632 g, 7.27 mol) in portions at 0 ° C. under a nitrogen atmosphere. The resulting mixture was stirred at RT under a nitrogen atmosphere. After 12 h, the solid was collected by filtration and washed with DCM (500 mL×3). The filtrate was concentrated to dryness, and the resulting residue was purified by FCC (5:1, petroleum ether / ethyl acetate) to give 5,6-dihydro-7H-cyclopenta[b]pyridin-7-one (80 g, 58%) as a dark green solid. MS (ESI): mass calculated for CHNO is 133.0; m / z found is 134.2 [M+H] + .
[1566] Step E: (R)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol. To a stirred solution of bromo(ethynyl)magnesium (1.4 L, 0.7 mol) at 0°C under a nitrogen atmosphere was added a solution of 5,6-dihydro-7H-cyclopenta[b]pyridin-7-one (80 g, 0.7 mol) in THF (800 mL) dropwise. The resulting mixture was stirred at RT under a nitrogen atmosphere for 2 h. Thereafter, the resulting mixture was cooled to 0°C and saturated aqueous ammonium chloride (1 L) was added. The resulting mixture was extracted with ethyl acetate (1 L x 3). The combined organic layers were washed with brine (1 L), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The resulting residue was purified by FCC (20:1, CH2Cl2 / MeOH) to give racemic 7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (56 g, 62%) as an off-white solid. The (R) and (S) enantiomers of racemic 7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (28 g) were separated by chiral preparative SFC (Chiral-IC 4.6×100 mm, 5 μm; co-solvent: MeOH (0.1% DEA); gradient (B%): 10% to 50% in 4.0 min, maintained at 50% for 2.0 min; flow rate: 4 ml / min) purification; temperature: 35°C; detector, UV 220 nm) separation to give (R)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (13.1 g, 47%, 97% ee) as an off-white solid and (S)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (Intermediate 39, 13.1 g, 47%, 97% ee) as an off-white solid. Data for (R)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol: MS (ESI): C 10The calculated mass of H9NO is 159.0; the found m / z is 160.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.61–8.41(m,1H),7.68–7.52(m,1H),7.24–7.15(m,1H),4. 36(s,1H),3.14–2.91(m,2H),2.78–2.68(m,1H),2.66(s,1H),2.58–2.36(m,1H). [α] 20 D =-81.9 (c=0.34, MeOH).
[1567] Intermediate 39: (S)-7-Ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol.
[1568]
[1569] Chiral separation described in Intermediate 38 provided (S)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (13.1 g, 47%, 97% ee) as an off-white solid. MS (ESI): C 10 The calculated mass of H9NO is 159.0; the found m / z is 160.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.61–8.41(m,1H),7.68–7.52(m,1H),7.24–7.15(m,1H),4. 36(s,1H),3.14–2.91(m,2H),2.78–2.68(m,1H),2.66(s,1H),2.58–2.36(m,1H). [α] 20 D =+81.1 (c=0.33, MeOH).
[1570] Intermediate 40: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one .
[1571]
[1572] Step A: 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidine. To a solution of (3-iodophenyl)methanamine (7.7 g, 33 mmol), 4-hydroxy-TEMPO (450 mg, 2.61 mmol) and o-xylene (30 mL) was added 3-amino-2-methoxyisonicotinaldehyde (2.0 g, 13 mmol) at RT. The resulting mixture was stirred at 120 °C under O2 (15 psi) for 16 h and then cooled to RT. The suspension was filtered and the filter cake was washed with ethyl acetate (20 mL x 3) and then dried under reduced pressure to give the title compound (1 g, 22%). The obtained title compound was recrystallized from ethyl acetate (5 mL) to give 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidine (770 mg, 17%) as a yellow solid. MS (ESI): C 14 H 10 The calculated mass of IN3O is 363.0; the found m / z is 363.9 [M+H] + .
[1573] Step B: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one. Into a 100 mL round-bottom flask was placed pyridine hydrochloride (13.0 g, 112 mmol) and 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidine (1.77 g, 4.87 mmol). The resulting mixture was stirred under N2 and 170°C for 3 h, then cooled to RT. The mixture was purified by FCC (20:1 to 0:1 gradient, petroleum ether / ethyl acetate) to give 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one (1.2 g, 70%) as a yellow solid. MS (ESI): C 13 The calculated mass of H8IN3O is 349.0; the found m / z is 349.9 [M+H] + .
[1574] Intermediate 41: 2-Methylsulfonylpyrido[3,4- d ]pyrimidin-8-amine .
[1575]
[1576] Step A: Methyl 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxylate. Into a 3 L, 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed methyl 5-bromo-2-(methylsulfonyl)pyrimidine-4-carboxylate (130 g, 494 mmol), 1,4-dioxane (1.5 L), 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (198 g, 999 mmol), Pd(dppf)Cl2 (10.9 g, 14.9 mmol), water (300 mL), and K3PO4 (233 g, 1.10 mol). The resulting solution was stirred at 80°C. After 16 h, the resulting mixture was poured into water (1.7 L) and extracted with ethyl acetate (2 L x 3). The combined organic layers were concentrated and the residue was purified by FCC (5:95, ethyl acetate / petroleum ether) to give methyl 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxylate (87, 69%) as a yellow solid. MS (ESI): C 11 H 14 The calculated mass of N2O3S is 254.3; the found m / z is 255.0 [M+H] + .
[1577] Step B: 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxamide. Into a 1 L sealed tube was placed methyl 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxylate (50 g, 197 mmol) and a solution of NH3 in MeOH (500 mL, 7N). The resulting solution was stirred at 55°C. After 2 h, the resulting mixture was concentrated to dryness to give 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxamide (47 g, solid), which was used in the next step without further purification. MS (ESI): C 10 H 13 The calculated mass of N3O2S is 239.3; the found m / z is 240.0 [M+H] + .
[1578] Step C: 2-(Methylsulfonyl)-7H,8H-pyrido[3,4-d]pyrimidin-8-one. In a 2 L round-bottom flask was placed 5-[(E)-2-ethoxyvinyl]-2-(methylsulfonyl)pyrimidine-4-carboxamide (46 g, 192 mmol), toluene (920 mL), and p-toluenesulfonic acid monohydrate (3.3 g, 19 mmol). The resulting solution was stirred at 90°C. After 2 h, the mixture was cooled to 0°C using an ice / salt bath. The resulting solution was diluted with 2 L of petroleum ether, and the resulting solid was collected by filtration and washed with petroleum ether (100 mL x 3). The resulting organic filtrate was concentrated to dryness to afford 2-(methylsulfonyl)-7H,8H-pyrido[3,4-d]pyrimidin-8-one (31.4 g, 85%) as a yellow solid. MS (ESI): mass calculated for C8H7N3OS: 193.2; m / z found: 194.0 [M+H] + .
[1579] Step D: 8-chloro-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine. Into a 1 L round-bottom flask was placed 2-(methylsulfonyl)-7H,8H-pyrido[3,4-d]pyrimidin-8-one (31.4 g, 163 mmol), ACN (500 mL) and POCl3 (73.7 g, 481 mmol). The resulting solution was heated at 70 ° C. After 2 h, the resulting mixture was concentrated to dryness. Water (1 L) was added portionwise to the resulting residue. The pH of the solution was adjusted to 8 using saturated aqueous sodium carbonate solution. The solid was collected by filtration and the filtrate was concentrated to dryness to give 8-chloro-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (32.1 g, 93%) as a brown solid. MS (ESI): mass calculated for C8H6ClN3S: 211.0; m / z found: 212.0 [M+H] + .
[1580] Step E: 2-(Methylsulfonyl)pyrido[3,4-d]pyrimidin-8-amine. Into a 1 L sealed tube was placed 8-chloro-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (32.1 g, 152 mmol) and a NH3 solution in IPA (320 mL, 2 M). The resulting solution was heated at 145°C. After 16 h, the resulting mixture was concentrated to dryness and purified by FCC (3:1, DCM / ethyl acetate) to give 2-(methylsulfonyl)pyrido[3,4-d]pyrimidin-8-amine (11.3 g, 39%) as a yellow solid. MS (ESI): mass calculated for CH8N4S is 192.1; m / z found is 193.0 [M+H]. + . 1H NMR (300MHz, DMSO-d6) δ9.3-9.2(m,1H),7.97-7.87(m,1H),7.06(s,2H),7.0-6.9(m,1H),2.7-2.6(m,3H).
[1581] Intermediate 42: 2-(5-bromo-2-isobutylphenyl)pyrido[3,4-d]pyrimidin-8-amine.
[1582]
[1583] Step A: 5-bromo-2-isobutylbenzonitrile. In a round-bottom flask, 5-bromo-2-iodobenzonitrile (1.9 g, 6.2 mmol), tri(furan-2-yl)phosphine (0.14 g, 0.61 mmol) and bis(dibenzylideneacetone)palladium (0) were added. The container was sealed with a septum, and the atmosphere was evacuated, then purged with N (3 ×). Anhydrous THF (20 mL) was charged into the container and allowed to stir at RT until the initial uniform red solution became uniform yellow (approximately 15 minutes). The resulting mixture was then treated with isobutyl zinc bromide (13 mL, 6.5 mmol, 0.5 M THF solution) and stirred for 30 min at RT. The mixture was diluted with CH Cl (20 mL), filtered through a diatomaceous earth pad and concentrated to dryness. The residue was purified by FCC to give 2-(5-bromo-2-isobutylphenyl)pyrido[3,4-d]pyrimidin-8-amine (1.2 g, 79%). MS (ESI): C 11 H 12 The calculated mass of BrN is 237.02; the measured m / z is 238.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.74-7.72(m,1H),7.64-7.60(m,1H),7.16(d,J=8.3Hz,1H),2.67(d,J=7.3Hz,2H),2.03-1.89(m,1H),0.95(d,J=6.6Hz,6H).
[1584] Step B: (5-bromo-2-isobutylphenyl)methylamine. In a 100mL round-bottom flask, a homogeneous solution of 5-bromo-2-isobutylbenzonitrile (1.4g, 5.9mmol) in anhydrous THF (20mL) was cooled to 0°C under an N2 atmosphere and then slowly treated with a BH3-THF complex (13mL, 13mmol, 1M THF solution). After complete addition of BH3-THF, the resulting solution was warmed to RT. A water-cooled reflux condenser was connected and the solution was heated at 75°C for 90min. The resulting mixture was then cooled to RT and acidified to approximately pH 2 with HCl (approximately 3mL, 1M). After 10 minutes, the pH of the mixture was adjusted to> pH 10 with 1M NaOH. The mixture was diluted with ethyl acetate (100mL) and washed with brine (100mL×2). The combined organic layers were dried (MgSO4), filtered and concentrated to near dryness. The residue was purified by FCC to give (5-bromo-2-isobutylphenyl)methanamine (1.2 g, 73%) contaminated with about 12% n-BuOH (w / w) and used without further purification. MS (ESI): C 11 H 16 The calculated mass of BrN is 241.05; the measured m / z is 242.1 [M+H] + . 1 HNMR (400MHz, CDCl3) δ7.52-7.49(m,1H),7.31-7.27(m,1H),6.99(d,J=8.1Hz,1 H), 3.85 (s, 2H), 2.46 (d, J = 7.3Hz, 2H), 1.86-1.74 (m, 1H), 0.91 (d, J = 6.6Hz, 6H).
[1585] Step C: 2-(5-bromo-2-isobutylphenyl)-8-chloropyrido[3,4-d]pyrimidine. 2-(5-bromo-2-isobutylphenyl)-8-chloropyrido[3,4-d]pyrimidine was prepared using conditions similar to those described in Step A of Example 53 using 3-amino-2-chloroisonicotinaldehyde and (5-bromo-2-isobutylphenyl)methanamine (462 mg, 29%). MS (ESI): C 17 H 15 The calculated mass of BrClN3 is 375.01; the measured m / z is 376.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ9.61 (s, 1H), 8.56 (d, J = 5.4Hz, 1H), 8.27 (d, J = 2.2Hz, 1H), 7.75 (d, J = 5.4Hz, 1H), 7 .57-7.51(m,1H),7.21(d,J=8.2Hz,1H),3.13(d,J=7.2Hz,2H),1.79-1.67(m,1H),0.82(d,J=6.6Hz,6H).
[1586] Step D: 2-(5-Bromo-2-isobutylphenyl)-N-(2,4-dimethoxybenzyl)pyrido[3,4-d]pyrimidin-8-amine. To a microwave vial was added a solution of 2-(5-bromo-2-isobutylphenyl)-8-chloropyrido[3,4-d]pyrimidine (0.45 g, 1.20 mmol) in anhydrous THF (3 mL), DIPEA (0.6 mL, 3.4 mmol), and (2,4-dimethoxyphenyl)methanamine (0.5 mL, 3.3 mmol). The vial was then crimped sealed and heated in a microwave reactor at 150°C for 1 h. The resulting heterogeneous mixture was then diluted with ACN (10 mL), briefly sonicated, filtered, and concentrated to dryness. The residue was purified by FCC to give 2-(5-bromo-2-isobutylphenyl)-N-(2,4-dimethoxybenzyl)pyrido[3,4-d]pyrimidin-8-amine (0.6 g, 90%). MS (ESI): C 26 H 27 The calculated mass of BrN4O2 is 506.13; the measured m / z is 507.3 [M+H] + . 1 H NMR (400MHz, CDCl3) δ9.29 (s, 1H), 8.16 (d, J = 5.8Hz, 1H), 8.02 (d, J = 2.2Hz, 1H), 7.51- 7.46(m,1H),7.31(d,J=8.2Hz,1H),7.24(t,J=5.9Hz,1H),7.15(d,J=8.2Hz,1H),6.86 (d,J=5.8Hz,1H),6.50(d,J=2.3Hz,1H),6.46-6.41(m1H),4.77(d,J=5.9Hz,2H),3.88 (s,3H),3.80(s,3H),2.90(d,J=7.1Hz,2H),1.66-1.54(m,1H),0.73(d,J=6.6Hz,6H).
[1587] Step E: 2-(5-bromo-2-isobutylphenyl)pyrido[3,4-d]pyrimidin-8-amine. A homogeneous solution of 2-(5-bromo-2-isobutylphenyl)-N-(2,4-dimethoxybenzyl)pyrido[3,4-d]pyrimidin-8-amine (0.57 g, 1.09 mmol) in THF (5 mL) was treated with TFA (7 mL) at room temperature and then heated at 80 ° C for 15 min. The resulting mixture was then cooled to RT and concentrated to dryness. The residue was dissolved in CHCl (10 mL) and DIPEA (1 mL) was added. The mixture was then concentrated to dryness and purified by FCC to give 2-(5-bromo-2-isobutylphenyl)pyrido[3,4-d]pyrimidin-8-amine (0.14 g, 37%). MS (ESI): C 17 H 17 The calculated mass of BrN4 is 356.06; the measured m / z is 357.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ9.37(s,1H),8.12(d,J=5.7Hz,1H),8.04(d,J=2.2Hz,1H),7.54-7.49(m,1H),7.18(d,J=8 .2Hz, 1H), 7.03 (d, J = 5.7Hz, 1H), 6.02 (s, 2H), 2.92 (d, J = 7.1Hz, 2H), 1.70-1.59 (m, 1H), 0.78 (d, J = 6.6Hz, 6H).
[1588] Intermediate 43: 8-amino-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one.
[1589]
[1590] Step A: 3-amino-2-chloroisonicotinic acid. A 500 mL round-bottom flask was charged with 3-aminoisonicotinic acid (5.0 g, 36 mmol) and concentrated HCl (110 mL, 37%). The mixture was cooled to 0°C and treated dropwise with 50% H2O2 (2.2 mL, 38 mmol). The resulting mixture was stirred at 0°C for 1 h and then at RT for 1 h. The resulting solid was isolated by filtration, rinsed with cold ACN (25 mL) and dried under high vacuum to give 3-amino-2-chloroisonicotinic acid (2.8 g, 45%), which was used without further purification. MS (ESI): mass calculated for C6H5ClN2O2 was 172.0; m / z found was 173.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ13.69(br s,1H),7.68-7.56(m,2H),6.85(br s,2H).
[1591] Step B: 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one. A sealable 100 mL round-bottom flask was charged with a solution of 3-amino-2-chloroisonicotinic acid (2.8 g, 16 mmol) and DIPEA (8.5 mL, 18 mmol) in DMF (40 mL). The mixture was cooled to 0°C and treated with a solution of 3-iodobenzoyl chloride (4.8 g, 18 mmol) in THF (2 mL). The resulting mixture was then warmed to RT and treated with additional 3-iodobenzoyl chloride (0.47 g). After 30 min, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (6.1 g, 16 mmol) was added in one portion, followed by heating at 60°C. After 1 h, the resulting mixture was then cooled to RT and treated with NH4OH (6 mL, 43 mmol, 28%). The vessel was then sealed and heated at 100 ° C for 3 h. The resulting mixture was then cooled to RT and concentrated to dryness. The residue was triturated with HCl (100 mL, 1 M), isolated by filtration, and dried under high vacuum to give 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one (3.5 g, 56%), which was used without further purification. MS (ESI): C 13 The calculated mass of H7ClIN3O is 382.93; the found m / z is 384.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ13.12 (s, 1H), 8.56 (s, 1H), 8.43 (d, J = 5.1Hz, 1H), 8.23 (d, J = 7.9Hz, 1H), 8.03-7.97 (m, 2H), 7.40 (t, J = 7.9Hz, 1H).
[1592] Step C: 8-((2,4-Dimethoxybenzyl)amino)-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one. 8-((2,4-Dimethoxybenzyl)amino)-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one was prepared using conditions similar to those described in Step D of Intermediate 42 and utilizing 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one. MS (ESI): C 22 H 19The calculated mass of IN4O3 is 514.05; the found m / z is 515.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.79(s,1H),8.69(s,1H),8.34(d,J=8.0Hz,1H),7.95(d,J=5.5Hz,2H),7.73(t,J=6.2Hz,1H),7.35(t,J=7.9Hz,1 H), 7.06 (d, J = 8.3Hz, 1H), 6.98 (d, J = 5.4Hz, 1H), 6.58 (d, J = 2.3Hz, 1H), 6.46-6.39 (m, 1H), 4.62 (d, J = 6.2Hz, 2H), 3.87 (s, 3H), 3.72 (s, 3H).
[1593] Step D: 8-amino-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one. 8-amino-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one was prepared using conditions similar to those described in Step E of Intermediate 42 and utilizing 8-((2,4-dimethoxybenzyl)amino)-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-4(3H)-one. MS (ESI): C 13 The calculated mass of H9IN4O is 363.98; the found m / z is 365.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.72(s,1H),8.73(s,1H),8.36(d,J=7.9Hz,1H),7.93(d,J=5.9Hz,2H),7.33(t,J=7.9Hz,1H),7.04-6.94(m,3H).
[1594] Intermediate 44: 4,8-Dichloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine.
[1595]
[1596] Step A: 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidin-4(3H)-one. A 500 mL round-bottom flask was charged with 3-amino-2-methoxyisonicotinic acid (20.0 g, 119 mmol), DIEA (73 mL, 416 mmol), and DMF (250 mL), followed by a solution of 3-iodobenzoyl chloride (34.8 g, 131 mmol, 1.10 equiv) in THF (100 mL). The yellow mixture was stirred at 25°C for 5 min. After 30 min, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (48 g, 125 mmol) was added. After 30min, NH4OH (98mL, 714mmol, 28.0% purity) was added, and the concentrated mixture was stirred for 30min. After this, the yellow mixture was heated at 120°C. After 12h, the resulting mixture was cooled and concentrated to dryness. The residue was suspended in HCl (1000mL, 1N) for 5min of ultrasonic treatment, and the solid was collected by filtration. The resulting solid was ground with THF (200mL) to obtain 2- (3- iodophenyl) -8- methoxypyrido [3,4-d] pyrimidine -4 (3H) -one (30g) as a yellow solid.
[1597] Step B: 4,8-dichloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine. A 1 L round-bottom flask was charged with 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidin-4(3H)-one (38 g, 100 mmol) and POCl3 (197 mL, 2.12 mmol). The yellow mixture was heated under N2 and 80°C for 12 h. The resulting mixture was allowed to stand at RT for 2 days, and then the mixture was concentrated to dryness. The residue was purified by FCC (100% DCM) to give 4,8-dichloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine (26 g, 63%) as a yellow solid.
[1598] Intermediate 45: (R)-3-ethynyl-3-hydroxy-1-(methyl-d 3 )pyrrolidin-2-one.
[1599]
[1600] Step A: 4-((tert-Butyloxycarbonyl)amino)-2-hydroxybutyric acid. Into a 5 L, 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 4-amino-2-hydroxybutyric acid (200 g, 1.67 mol) in water (1 L). This was followed by the addition of KCO (695 g, 4.99 mol) in several portions at 0°C. To this mixture was added dropwise a solution of di-tert-butyl dicarbonate (436 g, 2 mol) in dioxane (1 L) with stirring at 0°C. The resulting solution was stirred at 20-25°C for 24 h. The resulting mixture was washed with petroleum ether (1 L x 2). The combined aqueous phases were cooled to 0°C with a water / ice bath and adjusted to pH 4-5 with HCl (6N). The resulting solution was extracted with ethyl acetate (1 L x 4). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 4-((tert-butoxycarbonyl)amino)-2-hydroxybutanoic acid (260 g, 71%) as a yellow oil.
[1601] Step B: Methyl 4-((tert-Butoxycarbonyl)amino)-2-hydroxybutanoate. Into a 5 L, 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 4-[[(tert-Butoxy)carbonyl]amino]-2-hydroxybutanoic acid (260 g, 1.19 mol) in N,N-dimethylformamide (2.5 L) and CsCO (503 g, 1.54 mol). After 10 min, iodomethane (202 g, 1.42 mol) was added dropwise to the mixture with stirring at room temperature. After 4.5 h, the mixture was poured into water / ice (2 L) and extracted with ethyl acetate (2 L x 2). The combined organic extracts were washed with brine (1 L x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. This afforded methyl 4-((tert-Butoxycarbonyl)amino)-2-hydroxybutanoate (180 g, 65%) as a yellow oil.
[1602] Step C: Methyl 4-((tert-butoxycarbonyl)amino)-2-((tert-butyldimethylsilyl)oxy)butanoate. Into a 5 L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of methyl 4-[[(tert-butoxy)carbonyl]amino]-2-hydroxybutanoate (180 g, 0.77 mol) in dichloromethane (1.8 L) and imidazole (108 g, 1.54 mol). This was followed by the addition of tert-butyl(chloro)dimethylsilane (231 g, 1.53 mol) in several portions at 0° C. The resulting solution was warmed to RT and stirred for 16 h. Thereafter, the mixture was poured into water / ice (1 L) and extracted with dichloromethane (1.5 L×3). The combined organic extracts were washed with br...
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof in R 1 H or -CH 3 ; R 2 H or -CH 3 ; R 3 H, -C 1 -C 5 Alkyl, -OCH 3 or -OC 1 -C 3 Haloalkyl; R 4 H or -CH 3 ; part for R aa H or -CH 3 ; R bb H, -CH 3 or -CF 3 ; R cc -CH 3 、-CD 3 or -CH 2 CF 3 ;part for E is N or CH; F is O, S, NH or NCH 3 ; R a H or -CH 3 ; R b H, D, -OH, F, -C 1 -C 5 Alkyl, -CH 2 OCH 3 , -C 1 -C 5 Haloalkyl, -NH 2 , cyclopropyl or -CH 2 OH; R c H, D or -CH 3 ; R d H, -CN, -CF 3 , -C 1 -C 5 Alkyl, -C 3 -C 6 Cycloalkyl, -OC 1 -C 3 Alkyl, -N(R 6 )R 7 , in R 6 H or -C 1 -C 3 alkyl; R 7 H, -C 1 -C 3 Alkyl, -SO 2 CH 3 、-COCH 3 , -C 1 -C 4 Haloalkyl or -CH 2 CN, or R 6 and R 7 Together with the nitrogen to which they are attached, they form part Where m is 0 or 1, and p is 0 or 1; R 8 H, F or -C 1 -C 3 alkyl; R 9 H, F or -C 1 -C 3 alkyl; R e H, -CD 3 ,Br,-C 1 -C 5 Alkyl, -C 3 -C 6 Cycloalkyl, or 1 to 3 R g -C 1 -C 5 Alkyl, where R g For -NH 2 or F; R 10 is H or F; R 11 is H or F; R f H, -CH 3 or R h -CH 3 、-NH 2 or R i H, -CH 3 、-CN、Br、 R j For -NH 2 or R k H, -CF 3 、I、Cl、Br、-CN、-C 1 -C 6 alkyl, R 12 H or -CH 3 ; R 13 H, -CH 3 、-CH 2 (C)(CH 3 ) 2 OH, -(CH 2 ) 3 CN or - (CH 2 ) 2 NH 2 ; R 14 H or -CH 3 ; R l H, -C 1 -C 4 Alkyl, -CF 3 , R m H or -CH 3 ; R n For -NH 2 ; R o H or -CH 3 ; R p H or -CH 3 ; R q H, -CN, F, Cl, -OCH 3 , -CF 3 or -CH 3 ; and R s For -NH 2 or The prerequisite is that part for And each R 1 , R 2 , R 3 and R 4 When H, then part for 2. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in R 1 H or -CH 3 ; R 2 H or -CH 3 ; R 3 H, -C 1 -C 5 Alkyl, -OCH 3 or -OC 1 -C 3 Haloalkyl; R 4 H or -CH 3 ; part for R cc -CH 3 、-CD 3 or -CH 2 CF 3 ; part for E is N or CH; F is O, S, NH or NCH 3 ; R a H or -CH 3 ; R b H, D, -OH, F, -C 1 -C 5 Alkyl, -CH 2 OCH 3 , -C 1 -C 5 Haloalkyl, -NH 2 , cyclopropyl or -CH 2 OH; R c H, D or -CH 3 ; R d H, -CN, -CF 3 , -C 1 -C 5 Alkyl, -C 3 -C 6 Cycloalkyl, -OC 1 -C 3 Alkyl, -N(R 6 )R 7 , in R 6 H or -C 1 -C 3 alkyl; R 7 H, -C 1 -C 3 Alkyl, -SO 2 CH 3 、-COCH 3 , -C 1 -C 4 Haloalkyl or -CH 2 CN, or R 6 and R 7 Together with the nitrogen to which they are attached to form the moiety Where m is 0 or 1, and p is 0 or 1; R 8 H, F or -C 1 -C 3 alkyl; R 9 H, F or -C 1 -C 3 alkyl; R e H, -CD 3 ,Br,-C 1 -C 5 Alkyl, -C 3 -C 6 Cycloalkyl, or 1 to 3 R g -C 1 -C 5 Alkyl, where R g For -NH 2 or F; R 10 is H or F; R 11 is H or F; R f H, -CH 3 or R h -CH 3 、-NH 2 or R i H, -CH 3 、-CN、Br、 R j For -NH 2 or R k H, -CF 3 、I、Cl、Br、-CN、-C 1 -C 6 alkyl, R 12 H or -CH 3 ; R 13 H, -CH 3 、-CH 2 (C)(CH 3 ) 2 OH, -(CH 2 ) 3 CN or -(CH 2 ) 2 NH 2 ; R 14 H or -CH 3 ; R l H, -C 1 -C 4 Alkyl, -CF 3 , R m H or -CH 3 ; R n For -NH 2 ; R o H or -CH 3 ; R p H or -CH 3 ; R q H, -CN, F, Cl, -OCH 3 , -CF 3 or -CH 3 ; and R s For -NH 2 or The prerequisite is that part for And each R 1 , R 2 , R 3 and R 4 When H, then part for 3. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in part for And part for The prerequisite is that when the said part for And R 1 , R 2 , R 3 and R 4 When H, the part for 4. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in part for And part for 5. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in part for And part for 6. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in part for And part for 7. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in R 1 is H; R 2 is H; R 3 is H; R 4 is H; part for And part for 8. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof in R 1 is H; R 2 is H; R 3 H or -C 1 -C 5 alkyl; R 4 is H; part for And part for 9. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in R 1 is H; R 2 is H; R 3 H or -C 1 -C 5 alkyl; R 4 is H; part for And part for 10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein part for
